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ABSTRACT 
 
Accumulating evidence has shown a significant relationship between the GI 
microbiota and GI health of the host. An alteration in the intestinal microbial community 
structure, referred to as intestinal dysbiosis, can significantly affect host GI health and 
play a pivotal role in the pathogenesis of GI diseases. This study aimed to evaluate the 
relationship between an enteric pathogen and intestinal dysbiosis, and to describe the 
functional aspects of the intestinal microbiota in dogs with GI diseases. Firstly, this 
study evaluated the relationship between diarrhea, intestinal dysbiosis, and the presence 
of C. perfringens by quantitative PCR and its enterotoxin (CPE) by ELISA in feces. The 
presence of CPE as well as fecal dysbiosis were associated with GI disease. However, 
the presence of C. perfringens was not indicative of GI disease. Furthermore, an 
increased abundance of enterotoxigenic C. perfringens may be a feature of intestinal 
dysbiosis that is associated with GI disease. Secondly, this study characterized fecal 
concentrations of short-chain fatty acids (SCFAs) in dogs with clinical signs of chronic 
GI disease. Dogs with clinical signs of chronic GI disease had decreased fecal 
concentrations of acetate, propionate, and total short-chain fatty acids. Finally, this study 
characterized the fecal microbiota and serum metabolite profiles in dogs with idiopathic 
inflammatory bowel disease (IBD) by using 454-pyrosequencing of 16S rRNA genes 
and an untargeted metabolomics approach. This study also evaluated the effects of 3 
weeks of medical treatment on both the GI microbiota and serum metabolite profiles in 
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dogs with IBD. Significantly lower bacterial diversity and distinct microbial 
communities were observed in dogs with IBD compared to healthy control dogs. Based 
on the metabolite profiles, this study identified several potential biomarkers. Although a 
clinical improvement was observed after medical therapy in all dogs with IBD, this was 
not accompanied by significant changes in the fecal microbiota or in serum metabolite 
profiles, suggesting an ongoing intestinal disease process. In conclusion, the findings of 
these studies provided new insights into the pathogenesis of canine GI diseases and 
highlight the importance of balanced microbial communities for canine GI health.   
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
I.1 Microbial communities in the canine gastrointestinal tract 
The mammalian gastrointestinal (GI) tract harbors trillions of microorganisms 
(bacteria, archaea, fungi, protozoa, and viruses), collectively termed the GI microbiota.1 
Bacteria are the most predominant domain and may represent more than 98% of GI 
microbiota.2,3 Due to physiological and environmental differences, the composition of 
the microbiota differs along the length of GI tract.1,4 In general, the microbiota increases 
in abundance along the GI tract, from the stomach to the colon. Anaerobic bacterial 
groups predominate in the distal portions of the GI tract, whereas a more equal 
distribution of aerobic and anaerobic bacteria has been observed in the proximal portions 
of the GI tract.4 This distribution of bacterial groups is similar to those observed in 
humans and other animal species including cats, a finding that highlights the genetic and 
environmental factors that play a major role in shaping the host microbiota.5,6  
A study using bacterial cultivation techniques reported that up to 106 cfu /g of 
bacteria are present in the canine stomach.7 Recent study using 454-pyrosequencing of 
16S rRNA genes, fluorescence in situ hybridization (FISH), and quantitative real-time 
PCR (qPCR), evaluated the microbial composition of gastric mucosal biopsies from 
healthy dogs.8 A median of 36 (range of 18–119) operational taxonomic units (OTUs) 
were detected. The majority of the sequences belonged to the phylum Proteobacteria 
(99.6%), with only a few sequences belonging to the phylum Firmicutes (0.3%). The 
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genus Helicobacter spp. was the most abundant genus (98.6 %) within the phylum 
Proteobacteria.8 
In studies using cultivation techniques, the reported duodenal bacterial counts 
ranged from 102 to 106 cfu/g of luminal content in healthy dogs.7,9 However, up to  109
cfu/g of bacteria have been reported in clinically healthy dogs.7,8 In duodenal mucosal 
biopsy samples from healthy dogs, 9 bacterial phyla, with Proteobacteria (average 
34.9%), Bacteroidetes (24.2%), Fusobacteria (20.7%), and Firmicutes (17.7%) being the 
most abundant, were identified in a study using 454-pyrosequencing of 16S rRNA 
genes.12 At the genus level, Fusobacterium spp. (14.5%), Bacteroides spp. (11.2%), and 
Clostridium spp. (7.2%) were the  most abundant in duodenal biopsy samples.12  
The total bacterial count in the jejunum was similar to that in the duodenum and 
was reported to be approximately 106 cfu/g.7 In a study using 454-pyrosequencing of 
16S rRNA genes, 10 different bacterial phyla were identified in jejunal luminal contents. 
The major bacterial phyla were Proteobacteria (46.7%), Firmicutes (15.0%), 
Actinobacteria (11.2%), Spirochaetes (14.2%), Bacteroidetes (6.2%), and Fusobacteria 
(5.4%). The most abundant bacterial classes were Gamma-proteobacteria (~40%), 
followed by Spirochaetes (~13%), Actinobacteria (~12%), Clostridia (~10%), 
Bacteroidetes (~6%), Fusobacteria (~4%), and Alpha-proteobacteria (~3%).13 
Along the small intestine, the ileum harbored the highest bacterial load 
(approximately 107 cfu/g) in healthy dogs.7 In a study analyzing constructed 16s rRNA 
gene clone libraries, the predominant bacterial phyla in luminal contents from the ileum 
were Fusobacteria, Firmicutes, and Bacteroidetes. At the order level, Fusobacteriales 
3 
(32.6%), Clostridiales (24.8%), Bacteroidales (22.7%), and Enterobacteriales (18.4%) 
dominated in ileal contents.4  
The large intestine harbors the highest density and diversity of microbial 
communities.4 The reported cultivated bacterial counts in the colon in dogs range 
between 109 to 1011 cfu/g with the predominant phyla being Fusobacteria, Bacteroidetes, 
and Firmicutes.4,7 Bacteroidales (30.3%) is the most predominant order in the colonic 
contents of healthy dogs, followed by Fusobacteriales (28.9%) and Clostridiales 
(26.1%).4 The microbial communities in feces have been studied intensively due to the 
noninvasive nature of sample collection and accessibility. The phylum Firmicutes, 
Bacteroidetes and Fusobacteria are the most predominant phyla reported in most 
studies.3,9,14–17 However, there are inconsistencies in regard to the reported proportions 
of these bacterial groups between studies. The reported proportion of Firmicutes ranged 
from 15% to >95% and the reported proportion of Bacteroidetes ranged from 0.1% to 
38%.3,16 These discrepancies between studies may be due to the differences in sample 
handling (e.g., storage condition, repeated freeze and thaw cycles of samples), DNA 
extraction protocols, targeted regions of the 16S rRNA gene, and the techniques utilized 
to characterize the microbiota.18,19 
I.2 Alterations of the canine intestinal microbiota in gastrointestinal disease 
An alteration of the intestinal microbial community structure, called intestinal 
dysbiosis, can significantly affect host GI health and play a pivotal role in the 
pathogenesis of various GI diseases.20–22 Intestinal dysbiosis may result in a 
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dysregulation of adaptive immune responses, and lead to inflammation and/or reduced 
immunological activity against infection.21 Furthermore, microbial disturbances may 
result in functional changes of the intestine, leading to altered intestinal permeability, 
and changes in metabolic functions (e.g., deconjugation of bile acids and reduced 
carbohydrate utilization) that lead to malabsorption and maldigestion.20 As a 
consequence, intestinal dysbiosis does not only affect the GI tract, but also the overall 
host health. In humans and rodent models, also a wide variety of extra-intestinal 
diseases, including diabetes mellitus, stress, asthma, and atopy, have been associated 
with intestinal dysbiosis.23,24 
With recent advances in high-throughput DNA sequencing technology, 
molecular approaches have become routine tools for ecological studies of the intestinal 
microbiota in the field of veterinary medicine and have revealed a highly diverse and 
complex intestinal ecosystem in the GI tract of dogs.3,4 Studies have also shown the 
presence of intestinal dysbiosis in dogs with various GI diseases.12,16,17,25–29 
I.2.1 Alterations of the canine intestinal microbiota in acute gastrointestinal 
disease 
Bell et al. assessed changes in the GI microbiota associated with acute episodes 
of diarrhea by using T-RFLP and qPCR, and observed large-scale changes of the GI 
microbiota during episodes of diarrhea.25 These included an increased abundance of 
Clostridiales (especially C. perfringens) and Enterococcus spp. In another recent study 
using 454-pyrosequencing of 16S rRNA genes, distinct fecal microbial communities 
were also observed between healthy control dogs and dogs with acute diarrhea.16 
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Authors also applied qPCR assays and found profound changes of specific bacterial 
groups in dogs with acute hemorrhagic diarrhea. While Blautia spp., Faecalibacterium 
spp., and Turicibacter spp. decreased, Sutterella spp. and C. perfringens increased 
significantly in dogs with acute hemorrhagic diarrhea compared to healthy dogs.16  
I.2.2 Alterations of the canine intestinal microbiota in chronic gastrointestinal 
disease 
Intestinal dysbiosis has also been observed in dogs with chronic GI disease. Jia et 
al. utilized FISH and DGGE to investigate the composition of the fecal microbiota in 
dogs with chronic diarrhea. FISH analysis revealed a significantly higher Bacteroides 
spp. count in dogs with chronic diarrhea compared to healthy control dogs.17 The 
proportion of the Lactobacillus–Enterococcus and Bifidobacterium spp. were not 
significantly different between control dogs and dogs with chronic diarrhea.17  
Allenspach et al. constructed 16S rRNA gene clone libraries from duodenal brush 
samples from healthy Greyhounds and German shepherd dogs with chronic 
enteropathy.27 At the phylum level, a higher abundance of Actinobacteria was observed 
in dogs with chronic enteropathy than in healthy controls.  At the order level, the 
abundances and frequencies of Lactobacillales, Actinomycetales, and Erysipelotrichales 
were significantly higher than those in healthy dogs. Within the order Lactobacillales, 
Streptococcus spp. and Abiotrophia spp. were more frequently found in dogs with 
chronic enteropathy than in healthy controls.27  
6 
I.2.3 Alterations of the canine intestinal microbiota in idiopathic inflammatory 
bowel disease 
Idiopathic inflammatory bowel disease (IBD) is a common chronic GI disorder in 
dogs.30 Similarly to humans, an interplay between the intestinal microbiota together with 
an underlying genetic susceptibility of the host and dietary and environmental factors, 
are implicated in the development of IBD.31 In humans with IBD, a lower abundance of 
Firmicutes and Bacteroidetes, and a higher abundance of Proteobacteria compared to 
healthy subjects have been observed.32 Similar changes in the small intestinal microbiota 
have been observed in dogs with IBD. Xenoulis et al. constructed 16S rRNA gene clone 
libraries from duodenal brush samples from healthy dogs and dogs with IBD.29 In this 
study, a significantly lower species richness and a significantly higher proportion of 
Enterobacteriaceae were observed in dogs with IBD.29 Suchodolski et al. applied the 
same technique to duodenal mucosal biopsies from dogs with IBD. These dogs had a 
significantly higher abundance of Proteobacteria and a significantly lower abundance of 
Clostridia.4 More recently, two studies evaluating the fecal microbiota reported a lower 
abundance of Faecalibacterium spp. in dogs with IBD.16,33 In addition to this finding, 
Rossi et al. also observed a lower abundance of Turicibacter spp..33 
Commonly observed alterations in the fecal microbiota in dogs with GI disease 
are decreases in Ruminococcaceae, Faecalibacterium spp., Turicibacter spp., and 
Bacteroidetes, with concurrent increases in Proteobacteria, specifically E. coli.16,33 
However, compared to what is known in humans, the information regarding the bacterial 
composition of the intestinal microbiota in dogs is still limited. Understanding changes 
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in the microbiota, together with the associated functional alterations may lay the 
foundation for future studies aiming to develop interventions (e.g., antibiotics, prebiotics 
or probiotics) to manipulate GI microbial communities in dogs with GI diseases.  
 
I.3 Functional aspects of the gastrointestinal microbiota 
Animals have co-evolved to exist with their GI microbiota in a mutualistic 
relationship where animals provide a uniquely suited environment for the microbiota in 
return for physiologic benefits provided to the host.1,21,34 The resident microbiota 
provides many health benefits to the host. For example, resident microbes are able to 
protect the host from invading pathogens.35 They aid in digestive processes and harvest 
energy from the diet that can be utilized by the host, thereby providing nutritional 
support for enterocytes.36 Furthermore, the presence of the enteral microbiota is an 
important trigger for the development and constant stimulation of the immune system.37 
In fact, an underdevelopment of lymphoid organs (e.g., Peyer’s patches, spleen) and 
immune cells (e.g., T-cells, dendritic cells, macrophages) was observed in germfree 
experimental animals.34,38,39  
The metabolic functions of micro-organisms are assumed to be one of the main 
evolutionary driving forces behind the coevolution of the GI microbiota with their host.40 
Molecular tools allow the identification of previously uncharacterized intestinal 
microbes and these techniques are also able to provide information about the 
functionality of the microbiome by means of metagenomics.31 High-throughput 
sequencing platforms enable a metagenomics approach (i.e., shotgun sequencing of 
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genomic DNA).41 This approach yields identification of host and microbial genes 
present in a sample, and offers an opportunity to assess the functional aspects of the 
microbiota.41 However, a genomic approach only provides a prediction of downstream 
biological events, because there are several downstream regulatory mechanisms 
including transcriptional/translational regulations and pathway interactions.42 Therefore, 
metabolomics, the study of downstream biochemical end products (metabolites), is 
deemed to have the potential to provide new insights into functional aspects of the GI 
microbiota (details follow below ).43,44 
 
I.4 Enteric pathogens in dogs 
Recent data suggest that the composition of the intestinal microbiota is an 
important factor for activation of virulence genes of some enteropathogens.45 For 
example, a study using a mouse model showed that specific patterns in intestinal 
microbial communities had a direct effect on the pathogenicity of Salmonella spp.46 The 
exact mechanisms behind this interplay between commensal bacteria and the virulence 
factors of enteropathogens have not been well elucidated. Recent reports have associated 
intestinal dysbiosis and changes in bacterial metabolism (e.g., altered short-chain fatty 
acid [SCFA] concentrations and bile acid profiles) with the activation of toxin 
production in patients with Clostridium difficile infection.47 There is evidence that 
alterations in intestinal bile acid composition enhance germination of C. difficile, 
increasing the susceptibility to infection.48,49 This suggests that there may be an 
important cross-talk between enteropathogens and commensals. In addition, 
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understanding the response of enteric pathogens to the changing intestinal environment 
may be the key to develop new ways to prevent and treat enteric infections. 
The invasion and/or colonization of the GI tract with specific pathogens may 
profoundly disturb the integrity of the intestinal epithelial barrier.50 Several potential GI 
pathogens have been recognized in dogs, including Clostridium difficile, Clostridium 
perfringens, Campylobacter jejuni, Salmonella spp., and E. coli.51 However, several of 
these potential enteropathogens are commensals in the GI tract and have been isolated at 
similar frequencies from diarrheic and non-diarrheic animals (e.g., C. perfringens and C. 
difficile).52 This complicates the clinical interpretation when presumptive 
enteropathogens are merely identified in the feces, as the isolation of those organisms 
from dogs does not always indicate the cause for the GI disease.51 Therefore, the cause-
effect relationship between those organisms and GI disease need to be interpreted with 
caution.  
One of the potential GI pathogens, Clostridium perfringens is a Gram-positive, 
spore-forming, anaerobic bacillus.53 This organism is a common inhabitant of the canine 
GI tract51 and responsible for a spectrum of diseases. C. perfringens enterotoxin (CPE) is 
thought to be an important virulence factor in dogs with C. perfringens-associated 
diarrhea.54 CPE is a single polypeptide, heat-labile protein with 35 kDa molecular 
weight. This enterotoxin is encoded by the C. perfringens enterotoxin gene (cpe gene) 
and synthesized during sporulation. After release from a sporulating cell, CPE induces 
toxicity by interacting with intestinal tight junctions, forming transmembrane pores on 
the cytoplasmic membrane and leading to altered epithelial permeability.53 In humans, 
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CPE is responsible for several GI diseases, including C. perfringens type A food 
poisoning,55 antibiotic-associated diarrhea,56 and nosocomial diarrheal disease.57 
Detection of CPE in feces from human patients with diarrhea is a criterion for the 
diagnosis of CPE-associated diarrhea.58 Several studies have evaluated the role of C. 
perfringens in dogs, and have reported C. perfringens as a potential cause of nosocomial 
diarrhea59 and acute hemorrhagic diarrhea.60,61 Clinical signs are usually mild and self-
limiting.51 Therefore, further diagnostic modalities, such as an endoscopy and abdominal 
exploration, are rarely conducted. Recently, evaluation of histopathological changes and 
the presence of bacteria in duodenal mucosal biopsies from dogs with acute hemorrhagic 
diarrhea revealed an increased abundance of mucosa-adherent C. perfringens in 6/9 of 
dogs, and demonstrated an association between the presence of this organism and the 
occurrence of acute hemorrhagic diarrhea.61 The author hypothesized C. perfringens 
may have a primary pathogenic role in dogs with acute hemorrhagic diarrhea.61 
Despite these studies, the exact role of C. perfringens in canine GI disease 
remains unknown, because this organism has been detected at similar isolation rates in 
healthy and diarrheic dogs.51,52,54,62 Moreover, limited information is available regarding 
the relationship between diarrhea, intestinal dysbiosis, and/or the presence of C. 
perfringens and its virulence factors CPE. The lack of understanding of these 
relationships may have led to inappropriate therapy (e.g., indiscriminate use of 
antibiotics) which may result in an undesired clinical outcome (i.e., further disturbance 
of the intestinal microbiota). To prevent this, studies evaluating the relationship between 
commensal bacteria and enteric pathogens in dogs are warranted. 
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I.5 Metabolomics 
Despite the well documented evidence that the intestinal microbiota play a role in 
the pathogenesis of  various GI diseases, the actual mechanisms of the host-microbe 
interactions remain elusive, but are believed to be mediated in part by microbial products 
(metabolites) that are derived from the intestinal microbiota and are locally and/or 
systemically absorbed by the host.34 Metabolomics is the comprehensive study of small 
molecules to evaluate cellular processes.63 Recent studies utilizing this approach have 
suggested that there may be various bacterial metabolites that play a significant role in 
GI health.64–67  
There are two main approaches to metabolomics. The first approach, targeted 
metabolomics, utilizes a variety of analytical methods and focuses on one or few specific 
metabolite(s).43 One example of targeted metabolomics is the measurement of serum 
concentrations of cobalamin (vitamin B12) and folate (vitamin B9). The measurement of 
these vitamins in serum has been utilized to diagnose GI disease in dogs for several 
years.68 The second approach, untargeted metabolomics, utilizes mass spectrometry 
platforms, including nuclear magnetic resonance (NMR) spectroscopy, gas 
chromatography/mass spectrometry (GC/MS), and liquid chromatography/mass 
spectrometry (LC/MS), and ion cyclotron resonance-fourier transform mass 
spectrometry (ICR-FT/MS) to identify hundreds of metabolites in biological samples 
simultaneously and thus provides global metabolite profiles, although the identity of all 
metabolites may not be known.43 
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I.5.1 Short-chain fatty acids 
Short-chain fatty acids (SCFAs) are primary end products of bacterial 
fermentation of non-digestible dietary fiber and have been the focus of many studies due 
to their immunomodulatory effects and their importance as an energy source for 
intestinal epithelial cells.69 SCFAs, primarily acetate, propionate, and butyrate, are 
produced through multiple pathways by the mutual relationship of different microbial 
groups.70  For example, the primary fermenters Bacteroidetes are able to transform 
simple sugars derived from the breakdown of complex carbohydrates to acetate. Then, 
butyrate producing bacteria (e.g., Clostridium spp.) further utilize acetate to generate 
butyrate. Propionate can be produced by Bacteroidetes and some Firmicutes (e.g., 
Lachnospiraceae) from lactate or succinate through the acetylate or succinate pathway, 
respectively.71,72  
Approximately 95% of SCFAs produced in the intestine are rapidly absorbed 
from the gut lumen either by directly crossing the epithelial barrier or by uptake through 
specialized transporters.73,74 Undissociated (i.e., unionized) SCFAs (< 5% of total 
SCFAs) can be transported from the apical surface into colonocytes by passive diffusion. 
On the other hand, the transport of dissociated (i.e., ionized) SCFAs (> 95% of total 
SCFAs) requires an active transport by several different transporters.69 The 
monocarboxylate transporter (MCT) 1 and the sodium-coupled monocarboxylate 
transporter (SMCT) 1 are highly expressed on the apical membrane of epithelia cells 
along the intestinal tract including the small intestine, the cecum, and the large 
intestine.73 SCFAs are cotransported with cations such as H+ and Na+.69 Therefore, 
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SCFAs absorption also stimulates water absorption and this mechanism provides an anti-
diarrheic effect.75  Although the identity of the actual transporter remains unidentified, a 
considerable amount of SCFAs seems to be transported via SCFA-HCO3- exchange.76 
SCFAs that are not utilized by epithelial cells are suspected to be transported across the 
basolateral membrane by other families of MCT, such as MCT4 and MCT5, or SCFA-
HCO3- exchange, and then reach the portal circulation.69 However, the exact mechanism 
for the basolateral transport remains elusive.  
SCFAs are also sensed by SCFAs receptors such as G-protein coupled receptors 
(GPRs), including GPR41 (also known as FFAR3), GPR43 (also known FFAR2), and 
GPR109A (also known as NIACR1).77,78 These receptors are expressed not only on 
intestinal epithelial cells but also on immune cells, adipocytes, endocrine L-cells and 
smooth muscle cells.79–82 The affinities of each receptor for SCFAs differ. The affinity of 
GPR 41 for SCFA in decreasing order is propionate, butyrate, and acetate; that of GPR 
43 is acetate and propionate followed by butyrate. GPR109A only has affinity for 
butyrate.78 
The degree of absorption and utilization differs for each SCFA. Butyrate is 
preferentially utilized as an energy source by intestinal epithelial cells, and only small 
amounts (<10%) of butyrate reach the portal circulation.83 In contrast, utilization of 
acetate and propionate by intestinal epithelial cells is limited. Therefore, most of acetate 
and propionate (up to 70%) enter the portal circulation and are metabolized in the liver 
and utilized as a source for lipid metabolism (acetate) and gluconeogenesis 
(propionate).36,83 Only acetate reaches the systemic circulation at relatively high 
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concentration and is utilized by muscle, heart, adipose tissue, and kidney.84 A small 
proportion of unabsorbed SCFAs are excreted in feces.84–87 
While the main role of SCFAs is to function as an energy source for intestinal 
epithelial cells and for further metabolism, several other physiological roles have been 
identified. While the exact mechanisms remain to be fully elucidated, two major 
mechanisms by which SCFAs exert physiological effects on the host have been 
proposed. The first mechanism is inhibition of histone deacetylase (HDAC).88 This 
mechanism can be achieved by direct action of intracellular SCFAs and/or indirect 
activation through GPRs signaling. The inhibition of HDAC promotes hyperacetylation 
of histones and can modify gene expression and cell differentiation.88 The second 
mechanism is signaling through GPRs.  As mentioned previously, these receptors are 
located on a variety of cells/tissues.34 Therefore, the systemic effects of SCFAs, 
including chemotaxis, stimulation of satiation through leptin production, regulation of 
GI motility, and immune cell development/differentiation, have been reported in studies 
in animal model and in vitro studies.77,81,89,90 Similarly, studies in cats have revealed the 
importance of SCFAs for proper intestinal function (e.g., maintenance of mucosal health 
and stimulation of longitudinal colonic smooth muscle), demonstrating their potential to 
increase intestinal motility and to provide an energy source in cats with colonic motility 
disorders .89,91  
Clinical studies in humans have revealed associations between fecal SCFAs 
concentrations and GI disorders such as IBD92 and colorectal cancer,93 and SCFAs are 
thought to confer a protective role against further disease progression.94 Regarding the 
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association between GI disease and SCFAs, the anti-inflammatory effect of SCFAs is of 
interest. Through these signaling transductions, SCFAs decrease the production of pro-
inflammatory cytokines such as IL-6, IL-8, and TNFα.82,95  Moreover, recent evidence 
shows the regulatory effect of propionate and butyrate on colonic regulatory T cells (T 
regs).90 Tregs from GF mice treated with SCFAs showed an increased expression of anti-
inflammatory cytokine IL-10 and Foxp3, which are crucial for suppressing immune 
response toward intestinal inflammation and the immune tolerance to commensal 
bacteria.96 Moreover, SCFAs treatment augmented the Tregs population and function 
through the GPR43 signaling mentioned above. Authors also demonstrated that these 
effects ameliorate the severity of induced colitis in mice.90  
SCFAs not only affect host physiology. The production of SCFAs provides an 
acidic luminal environment, which prevents overgrowth of pH-sensitive pathogenic 
bacteria, such as Enterobacteriaceae and Clostridia.70 Data from in vitro studies and 
experimental animal models suggest that the composition of intestinal microbiota and 
SCFAs are important factors for activation of virulence genes of some 
enteropathogens.35,46,97,98 Lawhon et al. reported on the effects of SCFAs on virulence 
genes of Salmonella typhimurium.98 These effects were shown to depend on the dose and 
composition of SCFAs, and were different between different SCFAs. At low total 
SCFAs concentration with a predominance of acetate, the expression of the invasion 
gene of Salmonella pathogenicity island (SPI-1) was induced.98  However, at high total 
SCFAs concentrations with a higher proportion of propionate and butyrate, the 
expression of the SPI-1 gene was suppressed.98 Similar findings, where propionate and 
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butyrate suppressed the expression of the SPI-1 gene have been reported in in-vitro 
studies.97,99   
In veterinary medicine, studies in dogs have mainly evaluated the effects of 
nutritional intervention on fecal SCFAs concentrations in healthy research dogs.100–102 
Limited information is available with regards to the status of fecal SCFAs in dogs with 
GI disease. Therefore, their role in the pathogenesis of canine GI disease is still 
unknown.  
I.5.2 Untargeted metabolomics 
Owing to the development of bioinformatics and analytical separation 
techniques, untargeted metabolomics, has been increasingly used in clinical studies in 
humans.103 Using mass spectrometry platforms, this approach can identify hundreds of 
metabolites in biological samples simultaneously, and therefore provides a 
comprehensive functional overview of biochemical pathways that are being up- or 
down-regulated during different physiologic or pathophysiologic states.43 Consequently, 
untargeted metabolomics is an emerging method for better understanding of disease 
pathophysiology and host-microbe interactions, with the potential to develop novel 
diagnostic markers and/or treatment approaches.92,104 While metabolomics studies have 
been applied in human patients with GI disease and have provided new insights into 
disease pathogenesis,42,103 only few studies have utilized this approach in veterinary 
clinical patients,64,65  and no studies using this approach have been reported in dogs with 
GI disease. One of the first metabolomics studies in human IBD patients, evaluated fecal 
extracts, and differentiated IBD patients from healthy controls.92 Decreased levels of 
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SCFAs and some ammonia derivatives were observed. This finding revealed a 
connection between IBD and dysbiosis.92 Further studies characterizing serum 
metabolite profiles in human patients with IBD have reported impaired amino acid and 
lipid metabolism.66,67,105 
As mentioned above, information about the intestinal microbiota and especially 
its functional aspects in dogs with GI disease is limited. Therefore, studies aiming to 
characterize the microbial composition and the metabolite profiles in healthy dogs and 
dogs with GI disease are warranted. These studies will improve our knowledge of the 
pathogenesis of various GI diseases in dogs and have the potential to aid in the 
development of new biomarkers and new treatments and/or drug targets, which 
ultimately have the potential to improve the quality of life in dogs with GI disease. 
 
I.6 Hypotheses and specific objectives  
The hypothesis of this study is that dogs with GI disease have an altered microbial 
composition, an altered function of the intestinal microbiota, and altered metabolite 
profiles compared to healthy control dogs.  
The objectives of the proposed research project are 1) to characterize the microbial 
composition within the intestinal tract of healthy control dogs and dogs with various GI 
diseases, 2) to evaluate the relationship between enteric pathogens and commensal 
bacteria, and 3) to describe the functional aspects of the intestinal microbiota by 
characterizing bacterial metabolite concentrations in healthy control dogs and dogs with 
GI diseases
*Reprinted with permission from Prevalence of Clostridium perfringens, Clostridium perfringens
enterotoxin and dysbiosis in fecal samples of dogs with diarrhea. By Minamoto Y, Dhanani N, Markel 
M.E., Steiner JM, Suchodolski JS., 2014. Veterinary Microbiology, 174(3-4):463-473, Copyright 2014 by 
Elsevier B.V  
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CHAPTER II 
PREVALENCE OF CLOSTRIDIUM PERFRINGENS, CLOSTRIDIUM PERFRINGENS 
ENTEROTOXIN AND DYSBIOSIS IN FECAL SAMPLES OF DOGS WITH 
DIARRHEA* 
II.1 Overview 
Clostridium perfringens has been suspected as an enteropathogen in dogs. 
However, its exact role in gastrointestinal (GI) disorders in dogs remains unknown. 
Recent studies suggest the importance of an altered intestinal microbiota in the 
activation of virulence factors of enteropathogens. The aim of this study was to evaluate 
the relationship between diarrhea, dysbiosis, and the presence of C. perfringens and its 
enterotoxin (CPE). Fecal samples were collected prospectively from 95 healthy control 
dogs and 104 dogs with GI disease and assessed for bacterial abundances and the 
presence of CPE using quantitative PCR and ELISA, respectively. C. perfringens was 
detected in all dogs. Potentially enterotoxigenic C. perfringens were detected in 33.7 % 
(32/95) of healthy control dogs and 48.1% (50/104) diseased dogs, respectively. CPE 
was detected by ELISA in 1.0% (1/95) of control dogs and 16.3% (17/104) of diseased 
dogs. Abundances of Fusobacteria, Ruminococcaceae, Blautia, and Faecalibacterium 
were significantly decreased in diseased dogs, while abundances of Bifidobacterium, 
Lactobacillus, and E. coli were significantly increased compared to control dogs. The 
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microbial dysbiosis was independent of the presence of the enterotoxigenic C. 
perfringens or CPE. In conclusion, the presence of CPE as well as fecal dysbiosis was 
associated with GI disease. However, the presence of C. perfringens was not indicative 
of GI disease in all cases of diarrhea, and the observed increased abundance of 
enterotoxigenic C. perfringens may be part of intestinal dysbiosis occurring in GI 
disease. The significance of an intestinal dysbiosis in dogs with GI disease deserves 
further attention. 
 
II.2 Introduction 
Clostridium perfringens is a commensal in the canine gastrointestinal (GI) tract51 
and responsible for a spectrum of diseases. C. perfringens enterotoxin (CPE) is thought 
to be an important virulence factor in dogs with C. perfringens–associated diarrhea.54 
CPE is encoded by the enterotoxin gene (cpe gene) and synthesized during sporulation. 
After release from sporulating cell, CPE induces toxicity by interacting with intestinal 
tight junctions, forming transmembrane pores on the cytoplasmic membrane and leading 
to altered epithelial permeability.53 In humans, CPE is responsible for several GI 
diseases including C. perfringens type A food poisoning,55 antibiotic-associated 
diarrhea,56 and nosocomial diarrheal disease.57 Detection of CPE in feces from human 
patients with diarrhea is a criterion for diagnosis of CPE-associated diarrhea.58 Several 
studies have evaluated the role of C. perfringens in dogs, and have reported C. 
perfringens as a potential cause of nosocomial diarrhea59 and acute hemorrhagic 
diarrhea.60,61 Clinical signs are usually mild and self-limiting. Therefore, further 
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diagnostic modalities, such as an endoscopy and abdominal exploration, are rarely 
conducted. Recently, evaluation of histopathological changes and the presence of 
bacteria in duodenal biopsies from dogs with acute hemorrhagic diarrhea revealed an 
increased abundance of mucosa-adherent C. perfringens in 6/9 of dogs.61  
However, despite these studies, the exact role of C. perfringens in canine GI 
disease remains unknown because this organism is detected at similar isolation rates in 
healthy and diarrheic dogs. Furthermore, these studies were conducted in a different 
country (i.e., Canada),54,106 used samples from shelter animals or referral 
hospitals,60,62,106,107 used a different ELISA assay,59 or used different detection methods 
(reverse passive latex agglutination assay [RPLAA]).62 There is currently also no gold 
standard for the diagnosis of C. perfringens-associated diarrhea in dogs. Therefore, 
confirmatory interpretation of data from different diagnostic assays (i.e., detection of the 
cpe gene by PCR and CPE by ELISA in fecal samples from dogs) is recommended.51 
Recently, molecular studies have evaluated the diverse bacterial communities in 
the canine GI tract, and have shown the presence of intestinal dysbiosis, defined as 
altered GI microbial communities, in dogs with GI diseases. Commonly observed 
alterations are decreases in Ruminococcaceae, Faecalibacterium, Turicibacter, and 
Bacteroidetes, with concurrent increases in Proteobacteria, especially E. coli.4,12,16,29,51,108 
Of particular interest is that, while it has been shown that GI inflammation induces GI 
dysbiosis,109 it is also thought that prolonged dysbiosis may aggravate intestinal 
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inflammation.110 Therefore, dysbiosis plays a pivotal role in the pathogenesis of 
GI disease.20–22 
Limited information is available regarding the relationship between diarrhea, 
dysbiosis, and/or the presence of an enteric pathogen and its virulence factors.  This is of 
importance, as recent studies suggest that activation of virulence factors of C. difficile 
and Salmonella is associated with dysbiosis and concurrent changes in metabolite 
profiles such as altered bile acid and short-chain fatty acid (SCFA) concentrations.46,49 
Therefore, this study first aimed to investigate the prevalence of C. perfringens and CPE 
in healthy dogs and dogs with clinical signs of GI disease. The second aim was to 
quantify the abundance of C. perfringens and enterotoxigenic C. perfringens by 
detecting C. perfringens 16S ribosomal RNA (16S rRNA) gene and C. perfringens 
enterotoxin gene (cpe gene), respectively. The third aim was to evaluate the relationships 
between diarrhea, dysbiosis, and the presence of C. perfringens and its enterotoxin 
(CPE). 
 
II.3 Materials and methods 
II.3.1 Fecal samples  
Fecal samples from healthy control dogs and dogs with clinical signs of GI 
disease were collected prospectively from April 2010 to June 2012. The protocol for 
sample collection was approved by the Texas A&M University Institutional Animal 
Care and Use Committee (#2012-83). 
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Healthy control dogs: A total of 95 privately owned dogs without clinical signs of GI 
disease (i.e., vomiting, diarrhea, anorexia, weight loss, etc.) within the past three months 
of sample collection were enrolled. Dogs that received antibiotics within the past three 
months were excluded. Fresh fecal samples were collected at home or at public dog 
parks, and transported on ice to the Gastrointestinal Laboratory. 
Diseased dogs: A total of 104 left-over fecal samples from submissions to the 
Gastrointestinal Laboratory at Texas A&M University were utilized for this study. These 
submissions were from dogs with clinical signs of GI disease (i.e., vomiting, diarrhea, 
anorexia, weight loss, etc.) based on the clinical history and were submitted for enteric 
pathogen testing and/or fecal biomarker testing. Only the first submission sample was 
utilized for this study when multiple samples from same dog were submitted. The time 
of fecal sample collection after onset of diarrhea varied between samples depending on 
the time the dog was presented to the veterinarian.   
II.3.2 Clinical history of dogs 
Questionnaires were sent to veterinarians who submitted fecal samples and the 
owners of healthy control dogs. The questionnaire was composed of three major parts: 
signalment of dogs (breed, age, sex, body weight, and body condition score), health 
status of dogs at time of fecal sample collection (presence of GI signs and its 
characteristics, duration of GI signs), and medical history of dogs (medication [use of 
antibiotics, probiotics, etc.], concurrent diseases). Dogs with clinical signs of GI disease 
were classified based on the type of diarrhea (acute, chronic, or non-diarrhea). Diarrhea 
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was characterized as acute in nature if present for < 3 weeks and chronic if present for ≥ 
3 weeks.  
II.3.3 Evaluation of the stability of CPE in fecal samples 
To test the stability of the CPE in fecal samples during shipping to the 
laboratory, the stability at different storage conditions was evaluated. Thirteen leftover 
fecal samples from dogs with clinical signs of GI disease were screened for CPE. Of 
these samples, 8 fecal samples were initially positive for CPE and 5 fecal samples were 
initially negative for CPE. These samples were subdivided into 8 aliquots, then 
evaluated at 4 time points (day 0, 2, 5, and 10) after having been stored at 3 storage 
conditions (room temperature, 4°C, and -20°C). Each aliquot was stored unprocessed in 
microcentrifuge tubes at each storage condition until processing for the ELISA. 
II.3.4 DNA extraction  
DNA was extracted from an aliquot of 100 mg (wet weight) of each fecal sample 
using a commercial DNA extraction kit (ZR Fecal DNA KitTM; Zymo Research 
Corporation, Irvine, CA) following the manufacturer’s instructions. The bead-beating 
step was performed on a homogenizer (FastPrep-24; MP Biomedicals, Santa Ana, CA) 
for 60 s at a speed of 4 m/s. Fecal DNA was stored at -80°C until analysis. 
II.3.5 Quantitative PCR (qPCR) assay 
The abundances of C. perfringens 16S rRNA gene and C. perfringens 
enterotoxin gene (cpe gene) in feces were evaluated by qPCR assays using published 
oligonucleotides (Table 1). Quantitative PCR for detection of C. perfringens 16S rRNA 
gene was conducted using a total volume of 10 μL, with the mastermix containing 5 μL 
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of SsoFastTM Probes supermix (Biorad Laboratories, Hercules, CA), 2.2 μL of water, 0.3 
μL of each forward and reverse primer (300 nM final concentration), 0.2 μL of the probe 
(200 nM final concentration), and 2 μL of DNA. The qPCR cycling conditions were: an 
initial incubation at 94°C for 10 min, 45 cycles of denaturation at 94°C for 10 s, 
annealing at 58 °C for 20 s, and extension at 70 °C for 10 s. The qPCR for the detection 
of the cpe gene in feces was conducted using a total volume of 10 μL, with the 
mastermix containing 5 μL of SsoFastTM Probes supermix, 2.35 μL of water, 0.25 μL of 
each primer (final concentration: 250 nM), 0.15 μL of the probe (150 nM final 
concentration), and 2 μL of DNA. The qPCR cycling conditions were: an initial 
incubation at 95°C for 2 min, 40 cycles of denaturation at 95°C for 5 s, and annealing for 
10 s at 55°C.  
To assess the abundances of bacterial groups, which previously have been shown 
to be altered in canine GI diseases (Rossi et al., 2014; Suchodolski et al., 2012a; 
Suchodolski et al., 2008; Suchodolski et al., 2012b; Suchodolski et al., 2012c; Xenoulis 
et al., 2008), qPCR assays were performed for total bacteria, Fusobacteria, 
Ruminococcaceae, Bifidobacterium spp., Blautia spp., Faecalibacterium spp., 
Lactobacillus spp., and E. coli. The assay conditions, the oligonucleotide sequences of 
primers and probes, and respective annealing temperatures were described previously 
(Suchodolski et al., 2012c). A commercial real-time PCR thermal cycler (CFX384 
Touch™ Real-Time PCR Detection System; Biorad Laboratories, Hercules, CA) was 
used for all qPCR assays and all samples were run in duplicate. 
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II.3.6 ELISA for CPE 
C. perfringens enterotoxin (CPE) was detected using a commercially available 
ELISA kit (C. perfringens Enterotoxin Test; TechLab, Blacksburg, VA). The test was 
performed according to the manufacturer’s instructions. Briefly, fecal samples (an 
amount equal to 3 mm of formed feces or 50 µl of liquid feces) were emulsified in 200 
µl of diluent and vortexed for 10 seconds. One hundred µl of the diluted sample was 
then transferred to the microassay well containing the detecting polyclonal antibody 
against the toxin. The ELISA reaction was evaluated spectrophotometrically using a 
commercial multi-mode microplate reader (Synergy 2 Multi-Mode Microplate Reader; 
BioTek, Winooski, VT) at 450 nm wavelength. Samples with optical density (OD)450 ≥ 
0.120 were considered positive, and samples with OD450 < 0.120 were considered 
negative. 
Table 1. Oligonucleotides used for the detection of the C. perfringens 16S rRNA gene 
and the C. perfringens enterotoxin gene. 
Target qPCR primers/probes Sequence (5’- 3’) 
Annealing 
temperature 
(°C) 
Ref 
C. perfringens 16S 
rRNA gene CPerf165F CGCATAACGTTGAAAGATGG 58 
111 
 CPerf269R CCTTGGTAGGCCGTTACCC  
 
CPerf187F 
(probe) FAM-TCATCATTCAACCAAAGGAGCAATCC-TAMURA  
     
C. perfringens 
enterotoxin gene cpe F AACTATAGGAGAACAAAATACAATAG 55 
112 
 cpe R TGCATAAACCTTATAATATACATATTC  
  cpe Pr (probe) FAM-TCTGTATCTACAACTGCTGGTCCA-TAMURA   
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II.3.7 Statistical analysis 
Datasets for healthy control dogs and dogs with clinical signs of GI disease were 
tested for normality using a Shapiro-Wilk test, and then compared using a Wilcoxon 
rank-sum test (for 2 groups) or Kruskal-Wallis tests with Dunn’s post-tests (> 2 groups) 
where appropriate. A p < 0.05 was considered significant. For the evaluation of GI 
microbiota, all data were adjusted for multiple comparisons using a Bonferroni 
correction and an adjusted p < 0.05 was considered significant. A Spearman's rank 
correlation coefficient was used to evaluate the correlation between the abundance of C. 
perfringens 16s rRNA gene and the cpe gene. All statistical analyses were conducted 
using a statistical software package (JMP® Pro version 10, SAS Institute Inc, Cary, NC).  
 
II.4 Results 
II.4.1 Clinical history of dogs 
A total of 95 fecal samples from healthy control dogs and 104 fecal samples from 
dogs with clinical signs of GI disease were utilized for this study. The median age of 
healthy dogs and dogs with clinical signs of GI disease was 3 years (range: 0.6 to 12 y) 
and 5 years (range: 0.4 to 15 y), respectively (p = 0.006; Figure 1). Of the healthy 
control dogs, 38 were male (3 intact, 35 castrated) and 57 female (4 intact, 53 spayed). 
Of the dogs with clinical signs of GI disease, 54 were male (11 intact, 43 castrated) and 
50 female (13 intact, 37 spayed). There was no significant difference between the gender 
between the two groups (p = 0.117). The median body weight of healthy control dogs 
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and dogs with clinical signs of GI disease was 23.9 kg (range: 3.0 to 83.2 kg) and 23.2 
kg (range: 1.5 to 106.0 kg), respectively (p = 0.856). A large variety of breeds was 
represented in this study population. The healthy control group consisted of dogs of 39 
breeds and the 3 most common breeds were mixed breed (19/95 [20.0%]), Labrador 
Retriever [18/95 (18.9%)], and Australian Shepherd (6/95 [6.3%]). The diseased group 
consisted of dogs of 51 breeds and the 3 most common breeds were Labrador Retriever 
(17/104 [16.3%]), mixed breed (15/104 [14.4%]), and German Shepherd dogs (7/104 
[6.7%]). None of the healthy control dogs received antibiotics for at least 3 months 
before sample collection.  Of the dogs with clinical signs of GI disease, 38 dogs received 
antibiotics at the time of sample collection, while 58 dogs did not receive antibiotics at 
the time of sample collection, and 8 dogs had an unknown history of antibiotic 
administration. 
II.4.2 Evaluation of the stability of CPE in fecal samples 
A total of 104 fecal aliquots made from 8 CPE positive and 5 CPE negative fecal 
samples were analyzed to evaluate the stability of CPE over 10 days for the 3 storage 
conditions. All fecal aliquots were consistent with the initial result, regardless of storage 
condition or time (Table 2). 
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Figure 1. Distribution of ages in healthy control dogs and dogs with signs of GI disease. 
The lines represent the medians of both groups. 
Table 2. Results of CPE stability study. Each value represents OD450 value. Sample with 
OD450 ≥0.120 was considered positive, and sample with OD450 <0.120 was considered 
negative. 
   Time point and storage condition 
   Day 0  Day 2  Day 5  Day 10 
Sample  
Initial 
result     RT 4°C  RT 4°C  RT 4°C -20°C 
1 positive   0.765  0.631 0.770  0.477 0.388  1.241 0.574 0.589 
2 positive   0.181  0.495 0.338  0.408 0.215  0.269 0.393 0.274 
3 positive   0.258  0.602 0.371  0.413 0.297  0.466 0.525 0.464 
4 positive   0.609  0.646 0.820  0.802 0.248  0.531 0.882 0.563 
5 positive   0.556  0.756 0.574  0.621 0.519  0.492 0.611 0.694 
6 positive   1.956  1.371 1.501  1.968 1.934  1.077 1.722 1.840 
7 positive   0.843  0.947 0.864  0.549 0.510  0.492 1.097 0.749 
8 positive   0.220  0.275 0.426  0.457 0.263  0.530 0.224 0.394 
9 negative   0.045  0.048 0.042  0.041 0.059  0.069 0.051 0.048 
10 negative   0.048  0.099 0.046  0.045 0.047  0.061 0.055 0.060 
11 negative   0.045  0.049 0.069  0.045 0.051  0.046 0.048 0.081 
12 negative   0.046  0.041 0.049  0.063 0.053  0.044 0.065 0.050 
13 negative    0.050  0.053 0.082  0.041 0.063  0.049 0.057 0.048 
Each value represents OD450 value. Sample with OD450 ≥ 0.120 was considered positive, and 
sample with OD450 < 0.120 was considered negative. ELISA, enzyme-linked immunosorbent assay; 
RT, room temperature 
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II.4.3 Prevalence of C. perfringens (C. perfringens 16S rRNA gene) 
The C. perfringens 16S rRNA gene was detected in all samples from either 
healthy control dogs or dogs with clinical signs of GI disease. The abundance (i.e., 
amount of DNA) of the C. perfringens 16S rRNA gene was significantly higher in dogs 
with clinical signs of GI disease (p < 0.001) than in healthy control dogs. A subset 
analysis, in which dogs with clinical signs of GI disease were divided into 3 groups 
based on the type of diarrhea, revealed that a significantly higher abundance of the C. 
perfringens 16S rRNA gene was observed in dogs with acute and chronic diarrhea 
compared to the healthy control dogs (p = 0.003 and 0.010, respectively; Figure 2A). No 
significant difference was observed between control dogs and those dogs with clinical 
signs of GI disease but without diarrhea, and between dogs with acute and chronic 
diarrhea (Figure 2A).  
II.4.4 Prevalence of potentially enterotoxigenic C. perfringens (C. perfringens 
enterotoxin gene; cpe gene) 
The prevalence of the cpe gene was 32/95 (33.7%) in healthy dogs and 50/104 
(48.1%) in dogs with clinical signs of GI disease, and was significantly different 
between the groups (p = 0.044; Table 3). The abundance (i.e., amount of DNA) of the 
cpe gene was significantly higher in dogs with clinical signs of GI disease than in 
healthy dogs (p = 0.021). A subset analysis, in which dogs with clinical signs of GI 
disease were divided into 3 groups based on the type of diarrhea, revealed that a 
significantly higher abundance of cpe gene was observed in dogs with acute diarrhea 
compared to healthy control dogs (p = 0.002), but no significant differences were 
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observed among other groups (i.e., between healthy control, chronic diarrhea, and non-
diarrheic groups; Figure 2B). Of the samples positive for the cpe gene, 15/82 (18.3%; 
healthy control dog, n = 1; dogs with acute diarrhea, n = 4; chronic diarrhea, n = 7; non 
diarrhea, n = 4) were positive for the enterotoxin (CPE), and 67/82 (81.7%) samples 
were negative for CPE. A significant positive correlation was observed between the 
abundances of the C. perfringens 16S rRNA gene and the cpe gene (r = 0.428, p < 0.001; 
Figure 2C). 
II.4.5 Prevalence of C. perfringens enterotoxin (CPE) 
The prevalence of CPE was significantly different (p < 0.001) between healthy 
control dogs and dogs with clinical signs of GI disease (1/95 [1.0 %] and 17/104 
[16.3%], respectively; Table 3). Fecal samples from dogs that were positive for CPE had 
significantly higher abundances of C. perfringens 16S rRNA gene and cpe gene 
compared to those dogs that were CPE negative (both p < 0.001; Figure3).  
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Figure 2. Abundances of the C. perfringens 16S rRNA gene (A) and the cpe gene (B) in 
healthy control dogs and dogs with clinical signs of GI disease, and correlation of the C. 
perfringens 16S rRNA gene and the cpe gene (C). The bottom and top of the box 
represent the 25th and 75th percentiles, and the line of the box represents the medians. 
Whiskers represent the 10th and the 90th percentile. Columns not sharing a common 
superscript are significantly different (p < 0.05). ACT, dogs with acute diarrhea; CHR, 
dogs with chronic diarrhea; NON, dogs with clinical signs of GI disease but without 
diarrhea 
 
 
 
 
 
Table 3. The prevalence of enterotoxigenic C. perfringens or C. perfringens 
enterotoxin in feces. 
 ACT                 (n = 22)  
CHR          
(n = 58)  
NON 
 (n = 24)  
Total GI disease 
(n =104)  
Healthy              
(n = 95)  
p-value                 
(Healthy 
vs. GI 
disease) 
cpe-gene            
positive 16  24  10  
50  
(48.1%)  
32 
(33.7%)  p = 0.044 
negative 6  34  14  
54  
(51.9%)  
63 
(66.3%)   
CPE            
positive 4  8  5  
17 
 (16.3%)  
1  
(1.0%)  p < 0.001 
negative 18  50  19  
87 
 (83.7%)  
94 
(99.0%)   
cpe-gene, C. perfringens enterotoxin gene; CPE, C. perfringens enterotoxin; ACT, dogs with 
acute diarrhea; CHR, dogs with chronic diarrhea; NON, dogs with clinical signs of GI disease 
but without diarrhea 
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Figure 3. Abundance of the C. perfringens 16S rRNA gene (A) and the cpe gene (B) in 
samples either positive or negative for CPE. The bottom and top of the box represent the 
25th and 75th percentiles, and the line of the box represents the median. Whiskers 
represent the 10th and the 90th percentile. *significantly different (p < 0.05) compared to 
the CPE negative samples. CPE neg, C. perfringens enterotoxin assay negative; CPE 
pos, C. perfringens enterotoxin assay positive 
 
 
 
II.4.6 Evaluation of the fecal microbiota 
Comparison between healthy control dogs and dogs with clinical signs of GI 
disease: The abundances of Fusobacteria (p < 0.001), Ruminococcaceae (p < 0.001), 
Blautia spp. (p < 0.001), and Faecalibacterium spp. (p < 0.001) were significantly 
decreased in dogs with clinical signs of GI disease, while the abundances of 
Bifidobacterium spp. (p < 0.001), Lactobacillus spp. (p < 0.001), and E. coli (p < 0.001) 
were significantly increased compared to healthy control dogs (Figure 4). No significant 
difference was observed in the abundance of total bacteria between healthy control dogs 
and dogs with clinical signs of GI disease (p = 0.888; Figure 4). A subset analysis, in 
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which dogs with clinical signs of GI disease were divided into 3 groups based on the 
type of diarrhea (i.e., either acute, chronic, or non-diarrhea), revealed that dogs with 
chronic diarrhea  had significantly decreased abundances of Fusobacteria (p = 0.002), 
Ruminococcaceae (p < 0.001), Blautia spp. (p < 0.001), and Faecalibacterium spp. (p < 
0.001) and significantly increased abundances of Bifidobacterium spp. (p = 0.001), 
Lactobacillus spp. (p < 0.001), and E. coli (p < 0.001) compared to healthy control dogs 
(Figure 5). Dogs with acute diarrhea and dogs with clinical signs of GI disease but 
without diarrhea had significantly decreased abundances of Ruminococcaceae (both p < 
0.001), Blautia spp. (both p < 0.001), and Faecalibacterium spp. (both p < 0.001) and 
significantly increased abundances of E. coli (p < 0.001, p = 0.027, respectively) 
compared to healthy control dogs (Figure 5). 
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Figure 4. Abundances of bacterial groups in healthy control dogs and dogs with clinical 
signs of GI disease. The bottom and top of the box represent the 25th and the 75th 
percentiles, and the line of the box represents the median. Whiskers represent the 10th 
and the 90th percentile. *significantly different (adjusted p < 0.05) compared to healthy 
control dogs.  
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Figure 5.  Abundances of bacterial groups in healthy control dogs and dogs with clinical 
signs of GI disease. The bottom and top of the box represent the 25th and the 75th 
percentiles, and the line of the box represents the median. Whiskers represent the 10th 
and the 90th percentile. Columns not sharing a common superscript are significantly 
different (adjusted p < 0.05). ACT, dogs with acute diarrhea; CHR, dogs with chronic 
diarrhea; NON, dogs with clinical signs of GI disease but without diarrhea 
 
 
 
Relationship between intestinal dysbiosis and the presence of the cpe gene: Based on 
the qPCR results, both healthy control dogs and dogs with clinical signs of GI disease 
were classified into 2 groups (cpe gene positive or negative; total 4 groups; Figure 6). 
There were no significant differences in the abundance of any bacterial group between 
dogs that were cpe gene positive and cpe gene negative within either the healthy control 
group or the disease group (Figure 6). The results indicated that the differences in 
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bacterial groups between diseased and healthy control dogs were generally independent 
of the presence of the cpe gene. 
 
 
 
 
Figure 6. Relationship between the presence of the cpe gene and the abundance of 
bacterial groups. The bottom and top of the box represent the 25th and the 75th 
percentiles, and the line of the box represents the median. Whiskers represent the 10th 
and the 90th percentile. Columns not sharing a common superscript are significantly 
different (adjusted p < 0.05). H_neg, healthy control dogs that were cpe gene negative; 
H_pos, healthy control dogs that were cpe gene positive; D_neg, dogs with clinical signs 
of GI disease that were cpe gene negative; D_pos, dogs with clinical signs of GI disease 
that were cpe gene positive 
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Relation between dysbiosis and the presence of CPE: According to the ELISA 
results, healthy control dogs and dogs with clinical signs of GI disease were classified 
into 2 groups (CPE positive or negative: total 3 groups). The healthy control dog that 
was positive for CPE was excluded from this analysis because only one sample was 
present in this group. There were no significant differences in the abundance of any 
bacterial groups between dogs with clinical signs of GI disease that were CPE positive 
and CPE negative, indicating that differences in bacterial groups between diseased and 
healthy control dogs were generally independent of the presence of CPE (Figure 7).  
II.4.7 Effects of antibiotics 
To evaluate if the administration of antibiotics had a confounding effect on the 
prevalence of enterotoxigenic C. perfringens, the prevalence of CPE, and the 
abundances of bacterial groups, samples from dogs with signs of GI disease were 
analyzed based on the history of antibiotic administration. No significant differences 
were observed in the prevalence of enterotoxigenic C. perfringens and CPE between 
dogs with signs of GI disease that receiving antibiotics and those not receiving 
antibiotics (p = 0.946 and 0.419, respectively). No significant differences were also 
observed when dogs were divided into 3 groups based on the type of diarrhea, and 
compared based on the history of antibiotics within each group (all p > 0.100). With 
regards to the effects on the abundance of bacterial groups, no significant differences 
were observed in the abundances of C. perfringens 16S rRNA gene, cpe gene, and any 
other bacterial group analyzed between dogs with signs of GI disease that receiving 
antibiotics and those not receiving antibiotics (Table 4).  
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Figure 7. Relationship between the presence of CPE and the abundance of bacterial 
groups. The bottom and top of the box represent the 25th and the 75th percentiles, and the 
line of the box represents the median. Whiskers represent the 10th and the 90th percentile. 
Columns not sharing a common superscript are significantly different (adjusted p < 
0.05). H_neg, healthy control dogs that were CPE negative; D_neg, dogs with signs of 
GI disease that were CPE negative; D_pos, dogs with signs of GI disease that were CPE 
positive 
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II.5 Discussion  
A previous study reported the effects of storage on the detection of CPE by 
RPLA in canine fecal samples stored for 24 hours at 25°C and 4°C. Although there were 
some samples with a discordant RPLA result, overall no significant differences among 
storage conditions were reported.113 To exclude the possibility that lack of stability of 
CPE during long-term storage confounded our results, the stability of CPE as assessed 
by ELISA was evaluated. The results indicate that CPE is stable in feces under the tested 
conditions. However, we have not tested and, therefore, cannot exclude the possibility 
that the ongoing production of enterotoxin due to environmental changes and storage 
may yield a false positive result as assessed by ELISA. 
Table 4. Abundance of bacterial groups in dogs with signs of GI disease that did or 
did not receive antibiotics at the time of sample collection. 
  Dogs WITHOUT antibiotics (log DNA)  
Dogs WITH antibiotics 
(log DNA)  Adjusted 
p-value Target organism  Median  Range  Median  Range  
C. perfringens  5.3  (1.2-7.2)  5.0  (1.0-9.6)  1.0 
Enterotoxigenic C. perfringens  2.9  (0.0-8.4)  0.0  (0.0-7.8)  1.0 
Fusobacteria  7.5  (5.2-9.7)  7.3  (5.7-9.5)  1.0 
Ruminococcaceae  8.0  (5.2-8.6)  7.7  (6.0-9.0)  1.0 
Bifidobacterium spp.  5.6  (3.7-7.5)  5.6  (3.2-8.1)  1.0 
Blautia spp.  9.9  (6.5-10.7)  9.5  (6.9-10.8)  1.0 
Faecalibacterium spp.  4.5  (2.3-6.8)  4.8  (1.4-7.8)  1.0 
Lactobacillus spp.  6.3  (3.7-9.3)  6.4  (3.7-8.9)  1.0 
E. coli  7.3  (3.3-8.4)  7.3  (3.3-8.5)  1.0 
Total bacteria  10.7  (8.3-11.6)  10.9  (9.2-11.3)  1.0 
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In this study, C. perfringens was detected in all dogs based on the 16S rRNA 
gene. Potentially, enterotoxigenic C. perfringens (i.e., harboring the cpe gene) were 
detected in 33.7 % of control dogs and 48.1% of dogs with clinical signs of GI disease.  
These results are consistent with previous cultivation and/or PCR-based studies.52,54,60,106 
In previous reports, prevalence of CPE ranged between 5%54 and 16%60 in non-diarrheic 
dogs, and between 14%60 and 41% in diarrheic dogs.59 In our study, the prevalence of 
CPE in dogs with clinical signs of GI disease was similar with 16.3%. In contrast, the 
prevalence of CPE in control dogs (1.0%) was slightly lower than previously reported. 
The results of our stability study make it unlikely that this lower prevalence was due to 
sample degradation. Another possible explanation for lower prevalence may be due to 
geographical differences because all samples from control dogs were collected only in 
one state (i.e., Texas). In humans, the important role of CPE has been highlighted in 
acute diarrhea, but the role of CPE in chronic diarrhea has been rarely reported. In our 
current study, the prevalence of CPE was not significantly different between acute 
diarrhea and chronic diarrhea. Therefore,the role of CPE in chronic diarrhea warrants 
further evaluation. To conclude the first part of this study, dogs with clinical signs of GI 
disease had a significantly higher prevalence of enterotoxigenic C. perfringens compared 
to control dogs. However, its virulence factor CPE was detected in only 18.3% of dogs 
that were positive for enterotoxigenic strains. This indicates that the detection of C. 
perfringens by PCR for 16S rRNA gene and enterotoxigenic C. perfringens by PCR for 
the cpe gene is not always indicative of the presence of CPE in dogs with diarrhea.  
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The quantitative analysis revealed significantly higher abundances of both genes 
(16S rRNA gene for C. perfringens and cpe gene) in dogs with acute diarrhea compared 
to the control group. A recent study using sequencing of 16S rRNA gene showed 
changes in the fecal microbiome in dogs with acute diarrhea, and significant increases of 
C. perfringens in dogs with hemorrhagic diarrhea.16 In the current study, we evaluated 
the correlation between these genes, and found that the abundance of the cpe gene was 
positively correlated with the abundance of the C. perfringens 16S rRNA gene. These 
findings may suggest that increases in populations of enterotoxigenic C. perfringens are 
associated with acute diarrhea, but also that such an increase may be simply due to the 
increased overall population of C. perfringens with concurrent reduction of commensal 
microbiota (i.e., intestinal dysbiosis) as indicated by results of qPCR assays. Our results 
are also consistent with previous studies showing significant changes in abundances of 
several bacterial groups in dogs with GI diseases.4,12,16,29,108 Evaluating changes in the 
intestinal microbiota in GI disease are important for better understanding of disease 
pathogenesis. It has been well documented that the intestinal microbiota plays a crucial 
role in intestinal health, and that reduction of normal protective microbiota may confer 
susceptibility to intestinal inflammation. Prolonged imbalances of the GI microbiota may 
result in a dysregulation of immune responses and reduced activity against infection.21 
Furthermore, recent data suggest that the composition of intestinal microbiota and its 
associated metabolite profile is an important factor for activation of virulence genes of 
some enteropathogens. For example, a study using a mouse model showed that specific 
patterns in intestinal microbial communities had a direct effect on the pathogenicity of 
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Salmonella spp..46 The exact mechanisms behind this interplay between commensal 
bacteria and virulence factors of enteropathogens have not been well elucidated. Recent 
reports have associated intestinal dysbiosis and changes in bacterial metabolisms (e.g., 
altered SCFA and bile acid profiles) with the activation of toxin production in patients 
with C. difficile infection.47 There is evidence that alterations in intestinal bile acid 
composition enhance germination of C. difficile, increasing susceptibility to 
infection .48,49 This suggests an important cross-talk between enteropathogens and 
commensals.  
We observed an association between the abundance of enterotoxigenic C. 
perfringens and fecal dysbiosis, as the abundances of C. perfringens 16S rRNA gene and 
cpe gene were higher in dogs with diarrhea and these dogs had a dysbiosis manifested as 
reduction of several commensal bacterial groups.  Furthermore, there was a strong 
association between the presence of CPE and GI disease. This may suggest that the 
increased abundance of C. perfringens and enterotoxigenic C. perfringens may be part of 
dysbiosis and may not necessarily play a primary pathological role in diarrhea. However, 
it may also be possible that initial dysbiosis due to various causes and subsequent 
changes in bacterial metabolite profiles within the intestinal lumen may trigger the 
production of CPE from enterotoxigenic C. perfringens, as has been demonstrated with 
C. difficile. Further studies evaluating the activity of transcription of CPE are warranted. 
Clearly, the relationships between enteropathogens, fecal altered microbial communities, 
and altered bacterial metabolite profiles deserve further studies in dogs with GI disease.   
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There are several observations in this study that deserve discussion. There were 6 
samples from non-diarrheic dogs that were positive for CPE (5 dogs with clinical signs 
of GI disease but without diarrhea and 1 healthy control dog). Possible explanations for 
this are that there may be a threshold amount of enterotoxin required to cause diarrhea in 
dogs. For example, in food poisoning in humans due to enterotoxin produced by C. 
perfringens type A, a certain bacterial load is needed to induce disease.114 Other 
virulence factors of C. perfringens may play a role in canine diarrhea. Finally, it is 
important to note that the assay used here has limitations. The ELISA has not been 
properly validated for canine fecal samples. Therefore, potentially false positive results 
due to nonspecific binding, and potentially false negative results due to low binding 
affinity of the antibodies utilized towards canine isolates of C. perfringens should be 
considered.  Of all samples that were positive for the cpe gene, 67/82 (81.7%) samples 
were negative for CPE. This may suggest that abundance of CPE was below the 
detection limit of the ELISA assay or enterotoxigenic C. perfringens presented in feces, 
but enterotoxin was not produced due to the lack of spore formation. The latter 
explanation could be validated by quantifying spores. However, previous studies showed 
no statistical correlation between the presence of CPE and spore counts in feces.54,62 
Therefore, further studies investigating the CPE expression by evaluating RNA levels 
may provide the activity of CPE production. Finally, of samples negative for the cpe 
gene, 3/117 (2.5%) were positive for CPE. This suggests unspecific cross-reactivity in 
the ELISA assay. Alternatively, this finding may have been due to a low sensitivity of 
the qPCR assay.  
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There are some limitations to this study. There was a significant age difference 
between control dogs and dogs with clinical signs of GI disease. However, as Figure 1 
shows, the age range of control group did overlap with that of the disease group, thus, 
the statistically significant difference in age may not have been a major bias in this 
study. As mentioned previously, the CPE ELISA assay has not been validated for use in 
dogs, and its sensitivity and specificity are unknown. In the current study, we evaluated 
only one of the C. perfringens virulence factors and its encoding gene. Other virulence 
factors such as C. perfringens β2 toxin gene have previously been detected in diarrheic 
dogs,106,115 and a dog with fatal acute hemorrhagic gastroenteritis.116 Recent studies have 
identified three types of cpe loci organizations in C. perfringens type A isolate, and have 
suggest that there were differences in the pathogenesis between these types.58  Therefore, 
further evaluation of these genes may provide more information about the clinical 
significance of the isolated strains. The time of fecal sample collection after onset of 
diarrhea varied with sample in our study. This might confound the prevalence of CPE 
because detection of CPE is much more reliable when feces are collected early after the 
onset of diarrhea in humans. Lastly, we did not evaluate the presence of other potential 
enteric pathogens such as Campylobacter and Salmonella. Therefore, it is unknown that 
the cause of clinical signs was purely due to pathological effect of CPE.   
In conclusion, increased abundances of C. perfringens and enterotoxigenic C. 
perfringens were observed in dogs with clinical signs of GI disease, and these were most 
apparent in dogs with acute diarrhea. Although, the presence of CPE was associated with 
GI disease, the presence of this organism, either non- or enterotoxigenic strain, was not 
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indicative of GI disease in all cases of diarrhea.  On the other hand, dysbiosis was 
significantly associated with GI disease. Therefore, the increased abundance of C. 
perfringens and enterotoxigenic C. perfringens may be part of intestinal dysbiosis. It 
remains unknown whether dysbiosis is a cause or result of GI disease, and how dysbiosis 
affects enterotoxin production of C. perfringens. However, regardless of the initial cause 
of dysbiosis, an abnormal microbiota may exacerbate GI disease or may lead to 
metabolic changes in the intestinal lumen that may favor the activation of bacterial 
virulence genes in dogs with GI disease. These findings enlighten the importance of 
balanced microbial communities for GI health, and further evaluation of intestinal 
dysbiosis in dogs with GI disease is warranted. 
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CHAPTER III 
FECAL SHORT-CHAIN FATTY ACIDS CONCENTRATIONS IN DOGS WITH 
CHRONIC ENTEROPATHY 
 
III.1 Overview 
Accumulating evidence has suggested a significant relationship between the GI 
microbiota and host GI health. Microbial metabolites are believed to play a critical role 
in host-microbial interactions. Short-chain fatty acids (SCFAs) are major end-products 
of bacterial carbohydrate fermentation in the intestinal tract. They constitute an 
important energy source for intestinal epithelial cells and help maintain intestinal 
mucosal integrity. Decreased concentrations of SCFAs have been observed in humans 
with GI disease.  However, large scale clinical data are lacking in dogs. Therefore, the 
aim of this study was to evaluate fecal concentrations of SCFAs in healthy pet dogs and 
dogs with clinical signs of chronic GI disease.  
One fresh fecal sample was collected from each of 50 healthy control dogs and 
81 dogs with chronic enteropathy. Fecal concentrations of SCFAs (i.e., acetate, 
propionate, butyrate, and total short-chain fatty acids) were measured using gas 
chromatography/mass spectrometry. Fecal concentrations of SCFAs were normalized by 
dry matter and compared between both groups using a Wilcoxon rank-sum test. A p 
<0.05 was considered to be statistically significant. 
Fecal concentrations of acetate were significantly decreased (p = 0.049) in dogs 
with clinical signs of chronic GI disease (median: 193.4 [min-max: 20.1-1042.1] μmol/g 
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of fecal DM) compared to those in healthy control dogs (median: 218.7 [min-max: 87.7-
672.8] μmol/g of fecal DM). Also, fecal concentrations of propionate were significantly 
decreased (p <0.001) in dogs with clinical signs of chronic GI disease (median: 50.2 
[min-max: 0-227.9] μmol/g of fecal DM) compared to those in healthy control dogs 
(median: 104.6 [min-max: 1.6-266.8] μmol/g of fecal DM). Moreover, fecal 
concentrations of total short-chain fatty acids were significantly decreased (p = 0.012) in 
dogs with clinical signs of chronic GI disease (median: 272.3 [min-max: 21.7-1378.2] 
μmol/g of fecal DM) compared to those in healthy control dogs (median: 383.6 [min-
max: 126.6-927.0] μmol/g of fecal DM). However, there was no significant difference 
(p = 0.233) in fecal concentrations of butyrate between healthy control dogs (median: 
29.1 [min-max: 8.1-148.1] μmol/g of fecal DM) and dogs with clinical signs of chronic 
GI disease (median: 23.8 [min-max: 0-137.6] μmol/g of fecal DM). 
In this study, dogs with clinical signs of chronic GI disease had decreased fecal 
concentrations of acetate, propionate, and total short-chain fatty acids. The relationship 
between fecal short-chain fatty acid concentrations and microbial composition is 
warranted. 
 
III.2 Introduction 
Despite the well documented evidence that the intestinal microbiota plays a role 
in the pathogenesis of GI diseases, the actual mechanisms of the host-microbe 
interactions remain elusive, but are believed to be mediated in part by microbial products 
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(metabolites) that are derived from the intestinal microbiota and are locally and/or 
systemically absorbed by the host.34  
SCFAs are primary end products of bacterial fermentation of non-digestible 
dietary fibers. Because of their beneficial effects on host health, including 
immunomodulatory effects, anti-diarrheic effects and regulatory effect on GI motility, 
SCFAs have been the focus of many studies.75,87,89,117 SCFAs are also an important 
energy source for intestinal epithelial cells.87  
SCFAs, primarily acetate, propionate and butyrate, are produced through 
multiple pathways by the mutual relationship of different microbial groups.70  For 
example, the primary fermenters Bacteroidetes are able to transform simple sugars 
derived from the breakdown of complex carbohydrates to acetate and propionate. Then, 
secondly fermenters Firmicutes further utilize acetate to generate butyrate.71,72  
Absorption and utilization differs between different SCFAs. Butyrate is 
preferentially utilized as an energy source by intestinal epithelial cells, and only small 
amounts (<10%) of butyrate reach the portal circulation. In contrast, most of acetate and 
propionate (up to 70%) enter the portal circulation and are metabolized in the liver and 
utilized as a source for lipid metabolism (acetate) and gluconeogenesis (propionate). 
Only acetate reaches the systemic circulation in relatively high concentrations and is 
utilized by muscle, heart, adipose tissue, and kidney. A small proportion of unabsorbed 
SCFAs, are also excreted in feces.84–87  
Clinical studies in humans have revealed decreased fecal concentrations of 
SCFAs in patients with GI disorders such as IBD92 and colorectal cancer.93 Regarding 
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the association of GI diseases and SCFAs, the anti-inflammatory effect of SCFAs is of 
interest. As mentioned previously, SCFAs can regulate inflammation by increasing the 
production of pro-inflammatory cytokines (e.g., IL-10 and TGFβ), decreasing pro-
inflammatory cytokines (e.g., IL-6, IL-8, and TNFα), and activating transcription factor 
Foxp3.77,90 A study evaluating the effects of SCFAs in vitro and in vivo reported that 
treatment of SCFAs increased Treg population and enhanced its function, and ameliorated 
the severity of induced colitis in mice.90 SCFAs can not only affect the host physiology 
but also affect the GI microbiota. The production of SCFAs provides an acidic luminal 
environment that prevents overgrowth of pH-sensitive pathogenic bacteria, such as 
Enterobacteriaceae and Clostridia.70,118 Data from in vitro studies and experimental 
animal models suggest that composition of intestinal microbiota and SCFAs are 
important factors for activation of virulence genes of some enteropathogens.35,46,97,98  
In veterinary medicine, however, limited information is available with regards to 
fecal SCFAs in dogs with various GI diseases. Most of the studies mainly evaluated the 
effects of nutritional intervention on fecal concentrations of SCFAs in healthy research 
dogs.100–102 Therefore, their role in the pathogenesis of canine GI disease is still 
unknown. Therefore, we aimed to characterize fecal concentrations of SCFAs in healthy 
dogs and dogs with chronic GI disease. 
III.3 Materials and methods 
III.3.1 Fecal samples 
          Fecal samples from healthy control dogs and dogs with clinical signs of GI
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disease were collected prospectively from April 2011 to June 2013. The protocol for 
sample collection was approved by the Texas A&M University Institutional Animal 
Care and Use Committee (#2012-83). Fresh fecal samples were collected at home by the 
owners and immediately frozen, then transported on ice to the Gastrointestinal 
Laboratory. 
Healthy control dogs: A total of 50 privately owned dogs without clinical signs of GI 
disease (e.g., vomiting, diarrhea, anorexia, weight loss, or others) within the past three 
months of sample collection were enrolled. All dogs lived in diverse home environments 
and were fed a variety of commercial diets. Dogs that received antibiotics within the past 
three months were excluded 
Diseased dogs: A total of 81 left-over fecal samples from submissions to the 
Gastrointestinal Laboratory at Texas A&M University were utilized for this study. 
These submissions were from dogs with clinical signs of chronic GI disease (i.e., clinical 
signs including vomiting, diarrhea, anorexia, weight loss, others for a period of at least 3 
weeks) based on the clinical history and were submitted for fecal biomarker testing. The 
time of fecal sample collection after onset of diarrhea varied between samples depending 
on the time the dog was presented to the veterinarian.  The clinical status of each dog 
was evaluated using a published canine chronic enteropathy activity index (CCEAI). 
 III.3.2 Clinical history of dogs 
           Questionnaires were sent to veterinarians and owners who submitted fecal
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samples. The questionnaire was composed of three major parts: signalment of the dogs 
(i.e., breed, age, sex, body weight, and body condition score), health status of the dogs at 
time of fecal sample collection (i.e., presence of GI signs and its characteristics, duration 
of GI signs), medical history of dogs (i.e., medication [use of antibiotics, probiotics, 
etc.], concurrent diseases), and dietary information. 
  
III.3.3 Analysis of fecal SCFAs 
Concentrations of short-chain fatty acids (SCFA; acetate, propionate, and 
butyrate) in feces were measured using a stable isotope dilution gas chromatography-
mass spectrometry (GC-MS) assay as previously described119 with some modifications. 
Briefly, the fecal samples were weighed and diluted 1:5 in extraction solution (2N 
hydrochloric acid).  After homogenization by a multi-tube vortexer for 30 minutes at 
room temperature, fecal suspensions were centrifuged for 20 minutes at 2,100 x g at 
4°C. Supernatants were then collected using serum filters (Fisherbrand serum filter 
system, Fisher Scientific Inc, Pittsburgh, Pa). Of each sample, 500 μl of supernatant 
were mixed with 10 μl of internal standard (200mM heptadeuterated butyric acid) and 
extracted using a C18 solid phase extraction column (Sep-Pak C18 1 cc Vac Cartridge, 
Waters Corporation, Milford, MA). Samples were derivatized using N-tert-
butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) at room temperature for 60 
minutes. A gas chromatograph (Agilent 6890N, Agilent Technologies Inc, Santa Clara, 
CA) coupled with a mass spectrometer (Agilent 5975C, Agilent Technologies Inc, Santa 
Clara, CA) was used for chromatographic separation and quantification of the 
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derivatized samples. Separation was achieved using a DB-1ms capillary column (Agilent 
Technologies Inc, Santa Clara, CA). The GC temperature program was as follows: 40°C  
held for 0.1 min, increased to 70°C at 5°C/ min , 70°C held for 3.5 min, increased to 
160°C at 20°C /min, and finally increased to 280°C at 35°C/ min, then  held for 3 min. 
The total run time was 20.53 min. The mass spectrometer was operated in electron 
impact positive-ion mode with selective ion monitoring at mass-to-charge ratios (M/Z) of 
117 (acetate), 131 (propionate), 145 (butyrate), and 152 (deuterated butyrate; internal 
standard). Quantification was based on the ratio of the area under the curve of the 
internal standard and each of the fatty acids. Final concentrations of fecal SCFAs were 
adjusted by fecal dry matter (DM) and expressed as μmol/g of fecal DM.  
III.3.4 Statistical analysis 
Datasets for healthy control dogs and dogs with clinical signs of chronic GI 
disease were tested for normality using a Shapiro-Wilk test, and then compared using a 
Wilcoxon rank-sum test. A p < 0.05 was considered significant. All statistical analyses 
were conducted using a statistical software package (JMP® Pro version 10, SAS 
Institute Inc, Cary, NC).  
 
III.4 Results 
III.4.1 Signalment of dogs 
A total of 50 fecal samples from healthy control dogs and 81 fecal samples from 
dogs with clinical signs of chronic GI disease were utilized for this study. The median 
age of healthy dogs and dogs with clinical signs of chronic GI disease was 4.5 years 
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(min to max: 0.8 to 11.7 y) and 6.5 years (min to max: 0.5 to 12 y), respectively (p = 
0.041). Of the healthy control dogs, 26 were male (2 intact, 24 castrated) and 24 female 
(all spayed). Of the dogs with clinical signs of GI disease, 39 were male (6 intact, 33 
castrated) and 34 female (3 intact, 31 spayed). There was no significant difference 
between the gender between the two groups (p = 0.236). The median body weight of 
healthy control dogs and dogs with clinical signs of chronic GI disease was 17.9 kg (min 
to max: 1.5 to 42.2 kg) and 20.9 kg (min to max: 1.7 to 72.6 kg), respectively (p = 
0.256). A large variety of breeds was represented in this study population. None of the 
healthy control dogs received antibiotics for at least 3 months before sample collection.   
III.4.2 Evaluation of fecal SCFAs  
Fecal concentrations (median [min-max]) of acetate were significantly decreased 
(p=0.049; Figure 8 and Table 5) in dogs with clinical signs of chronic GI disease (193.4 
[20.1-1042.1] μmol/g of fecal DM) compared to those in healthy control dogs (218.7 
[87.7-672.8] μmol/g of DM). Also, fecal concentrations of propionate were significantly 
decreased (p<0.001; Figure 8 and Table 5) in dogs with clinical signs of chronic GI  
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disease (50.2 [0-227.9] μmol/g of fecal DM) compared to those in healthy control dogs 
(104.6 [1.6-266.8] μmol/g of DM). Moreover, fecal concentrations of total short-chain 
fatty acids were significantly decreased (p=0.012; Figure 8 and Table 5) in dogs with 
clinical signs of chronic GI disease (272.3 [21.7-1378.2] μmol/g of fecal DM) compared 
to those in healthy control dogs (383.6 [126.6-927.0] μmol/g of fecal DM). However, 
there was no significant difference (p=0.233; Figure 8 and Table 5) in fecal 
concentrations of butyrate between healthy control dogs (29.1 [8.1-148.1] μmol/g of 
fecal DM) and dogs with clinical signs of chronic GI disease (23.8 [0-137.6] μmol/g of 
fecal DM). Without adjusting for dry matter, fecal concentrations of all SCFAs were 
significantly decreased in dogs with clinical signs of chronic GI disease (Table 5). 
While the proportion of acetate increased in dogs with clinical signs of chronic 
GI disease (p = 0.015), the proportion of propionate decreased in dogs with clinical signs 
of chronic GI disease compared to healthy control dogs (p < 0.001; Figure 9). The 
proportion of butyrate did not differ between the 2 groups.  
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Figure 8. Fecal SCFAs concentrations in healthy control dogs and dogs with clinical 
signs of chronic GI disease. CE, dogs with clinical signs of chronic GI disease *p < 0.05 
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Table 5. Fecal SCFAs concentrations in healthy control dogs with dogs with clinical signs of chronic GI disease. 
 
WITH DM adjustment  
(μmol/g of fecal DM)  
WITHOUT DM adjustment  
(μmol/g of wet feces) 
 HC   CE     HC   CE   
SCFA Median Range    Median Range  p-value   Median Range    Median Range  p-value 
Acetate 218.7 87.7-672.8  193.4 
20.1-
1042.1 0.049  81.2 25.3-224  53.3 3.8-151.3 <0.001 
Propionate 104.6 1.6-266.8  50.2 0-227.9 <0.001  36.6 0.2-81.6  14.4 0-62.2 <0.001 
Butyrate 29.1 8.1-148.1  23.8 0-137.6 0.233  10.2 1.5-30.3  7.3 0-31.2 0.0071 
Total SCFAs 383.6 126.6-927.0   272.3 
21.7-
1378.2 0.010   129.8 
27.2-
292.9   72.2 4-229.3 <0.001 
CE, dogs with clinical signs of chronic GI disease; HC, healthy control dogs; SCFA(s), short-chain fatty acid(s); DM, dry matter 
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Figure 9. Composition of total fecal SCFAs in healthy control dogs and dogs with 
clinical signs of chronic GI disease. CE, dogs with clinical signs of chronic GI disease; * 
p < 0.05 
 
 
 
III.5 Discussion 
 In this study, dogs with clinical signs of chronic GI disease had decreased fecal 
concentrations of total SCFAs, specifically decreased concentrations of acetate and 
propionate. Without dry matter adjustment, fecal concentrations of all SCFAs were 
significantly decreased in dogs with clinical signs of chronic GI disease compared to 
healthy control dogs. 
While the fecal concentration of acetate was slightly decreased in dogs with 
clinical signs of chronic GI disease, its proportion (i.e., acetate/total SCFAs) was 
significantly increased in dogs with clinical signs of chronic GI disease. On the other 
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hand, the proportion of propionate was significantly decreased. These findings are of 
importance, as recent studies suggest that activation of virulence factors of C. difficile 
and Salmonella is associated with changes in SCFAs concentrations.46,49 Lawhon et al. 
reported on the effects of SCFAs on virulence genes of Salmonella typhimurium. At low 
total SCFA concentrations with a predominant of acetate, the expression of the invasion 
gene, SPI-1 gene, was induced.  However, at high total SCFA concentrations with a 
higher proportion of propionate, the expression of the SPI-1 gene was suppressed.98 
Similar findings where propionate and butyrate suppressed the expression of the SPI-1 
gene have been reported in in-vitro studies.97,99  
In the current study, the degree of change in concentration of propionate was 
prominent among all SCFAs. As mentioned above, propionate is metabolized in the liver 
and utilized as a source for gluconeogenesis. Therefore, the decreased concentration of 
propionate may lead to an alteration of energy metabolism in dogs with GI disease. In 
fact, the presence of altered energy metabolism was suspected based on the serum 
metabolite profiles in the other part of this study (chapter 5). Significant activation of the 
pentose phosphate pathway (an alternative pathway of glycolysis) and significant 
increased 3-hydroxybutyrate (ketone body), hexuronic acid (vitamin C), ribose, and 
gluconic acid lactone were observed in dogs with IBD (chapter 5). Propionate is also 
important because of its anti-inflammatory effect on intestinal inflammation. It has been 
shown that propionate decreases the production of pro-inflammatory cytokines such as 
IL-6, IL-8, and TNFα.120,121  Moreover, recent evidence shows the regulatory effect of 
propionate on colonic regulatory T cells (T regs).90 In this study the treatment of 
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propionate stimulated the expression of IL-10 and one of the transcription factors Foxp3. 
Activation of Foxp3 is crucial for suppression /regulation of intestinal inflammation. 
Moreover, treatment of propionate increased Tregs population and improved function 
through GPR43 signaling.90 Authors also demonstrated that these effects ameliorate the 
severity of experimental colitis in mice.90 Therefore, a decrease in concentration of 
propionate in dogs with clinical signs of chronic GI disease may affect immune system 
responses and resistance mechanisms against enteropathogens. 
Similar to our findings, studies in humans and rodent models have shown that 
decreased concentrations of SCFAs in the intestinal tract are associated with GI disease 
such as IBD and colorectal cancer.92,93 In these studies, the protective and therapeutic 
effects of SCFAs on GI disease have also been reported. Therefore, therapeutic 
interventions by manipulating SCFAs concentrations in the GI tract may be a promising 
treatment for suppressing intestinal inflammation and restore proper immune responses. 
Further research is warranted to determine the efficacy of SCFAs manipulation in dogs 
with GI disease.  
There are some limitations to this study. There was a significant age difference 
between the dogs in the control group and dogs with clinical signs of chronic GI disease. 
No studies have evaluated the effect of age on fecal concentrations of SCFAs. Therefore, 
the influence of age differences on this study is unknown. However, the age range of 
dogs in the control group did overlap with that of the disease group, thus, the statistically 
significant difference in age may not have created a major bias in this study. In our 
dataset, there were several outliers, and those samples tended to have a low fecal DM 
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value. This raised the question regarding normalization for fecal concentrations of 
SCFAs. While most of the studies evaluating fecal concentrations of SCFAs in dogs 
reported the concentrations adjusted by fecal DM (i.e., μmol/g of fecal DM), most of the 
clinical studies in humans reported the concentrations without adjustment to fecal DM 
(i.e., μmol/g of fecal content or wet feces). No consensus has been reached at this point 
whether normalization is necessary or not.  
In conclusion, this study demonstrated decreased concentrations and altered 
composition of SCFAs in dogs with clinical signs of chronic GI disease. Therefore, 
interventions manipulating SCFAs concentrations in the GI tract may prove to be a 
useful treatment for suppression of intestinal inflammation and to restore proper immune 
responses. Further research is warranted to determine the efficacy of SCFAs 
manipulation in dogs with GI diseases.
*Reprinted with permission from Alteration of the fecal microbiota and serum metabolite profiles in dogs
with idiopathic inflammatory bowel disease. By Minamoto Y, Otoni CC, Steelman SM, Büyükleblebici O, 
Steiner JM, Jergens AE, Suchodolski JS., 2015. Gut Microbes. 6(1):33-47, Copyright 2014 by Yasushi 
Minamoto 
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CHAPTER IV 
ALTERATION OF THE FECAL MICROBIOTA AND SERUM METABOLITE 
PROFILES IN DOGS WITH IDIOPATHIC INFLAMMATORY BOWEL DISEASE* 
IV.1 Overview 
Idiopathic inflammatory bowel disease (IBD) is a common cause of chronic 
gastrointestinal (GI) disease in dogs.  The combination of an underlying host genetic 
susceptibility, an intestinal dysbiosis, and dietary/environmental factors are suspected as 
main contributing factors in the pathogenesis of canine IBD. However, actual 
mechanisms of the host-microbe interactions remain elusive. The aim of this study was 
to compare the fecal microbiota and serum metabolite profiles between healthy dogs 
(n=10) and dogs with IBD before and after 3 weeks of medical therapy (n=12). Fecal 
microbiota and metabolite profiles were characterized by 454-pyrosequencing of 16S 
rRNA genes and by an untargeted metabolomics approach, respectively.  Significantly 
lower bacterial diversity and distinct microbial communities were observed in dogs with 
IBD compared to the healthy control dogs. While Gammaproteobacteria were 
overrepresented, Erysipelotrichia, Clostridia, and Bacteroidia were underrepresented in 
dogs with IBD. The functional gene content was predicted from the 16S rRNA gene data 
using PICRUSt, and revealed overrepresented bacterial secretion system and 
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transcription factors, and underrepresented amino acid metabolism in dogs with IBD. 
The serum metabolites 3-hydroxybutyrate, hexuronic acid, ribose, and gluconic acid 
lactone were significantly more abundant in dogs with IBD. Although a clinical 
improvement was observed after medical therapy in all dogs with IBD, this was not 
accompanied by significant changes in the fecal microbiota or in serum metabolite 
profiles. These results suggest the presence of oxidative stress and a functional alteration 
of the GI microbiota in dogs with IBD, which persisted even in the face of a clinical 
response to medical therapy.  
 
IV.2 Introduction 
The close relationship between the gastrointestinal (GI) microbiota and the host 
has a crucial impact on the health status of an animal.122 Intestinal dysbiosis, which 
describes an alteration of the GI microbiota, has been observed in human patients with 
chronic GI inflammation22 but also in dogs.12,16,28,29Idiopathic inflammatory bowel 
disease (IBD) is a common cause of chronic GI disease in dogs.  Similarly to human 
IBD, the combination of an underlying host genetic susceptibility, an intestinal 
dysbiosis, and dietary and/or environmental factors are suspected as main contributing 
factors in the pathogenesis of canine IBD.123–125 Furthermore, similarly to humans, 
intestinal inflammation develops spontaneously in dogs living in natural home 
environments, and the most frequently used treatment modalities for these disorders 
include antibiotic therapy and immunosuppression.126 
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Despite well documented evidence that the intestinal microbiota plays a role in 
the pathogenesis of canine IBD, the actual mechanisms of the host-microbe interactions 
remain elusive, but are believed to be mediated in part by microbial products 
(metabolites) derived from the GI microbiota and locally and/or systemically absorbed 
by the host.34 Therefore, studies that assess functional aspects of the GI microbiota are 
needed. Metabolomics, the comprehensive study of small molecules present in biological 
samples, is an emerging method for better understanding of disease pathophysiology and 
host-microbe interactions, with the potential to develop novel diagnostic and/or 
treatment approaches.92,104 Metabolomics studies have been reported in human patients 
with IBD as well as animal models of IBD, and provided new insights into disease 
pathogenesis.42,103 Using mass spectrometry platforms, an untargeted metabolomics 
approach can identify hundreds of metabolites in biological samples simultaneously, and 
therefore provides a comprehensive functional overview of biochemical pathways that 
are being up- or down-regulated during different physiologic or pathophysiologic state.43  
In veterinary medicine, only few studies have utilized this approach in clinical 
patients,64,65 and to our knowledge, no studies using an untargeted metabolomics 
approach have been reported in dogs with IBD. Therefore, we aimed to characterize the 
fecal microbiota and serum metabolite profiles in healthy dogs and compare those to 
dogs with IBD. We also investigated the effects of 3 weeks of medical intervention on 
these profiles. To investigate the global differences in GI microbial communities and 
metabolic profiles, we utilized 454-pyrosequencing of 16S ribosomal RNA (16S rRNA) 
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genes and an untargeted metabolomics approach using gas chromatography coupled with 
time-of-flight mass spectrometry (GC-TOF/MS).  
 
 
IV.3 Materials and methods 
IV.3.1 Animals and sample collection 
The collection and analysis of serum and fecal samples from healthy control dogs 
and dogs with IBD were reviewed and approved by the Texas A&M University 
Institutional Animal Care and Use Committee (#2012-83). Written informed consent 
was obtained from all owners of enrolled dogs. A blood sample was obtained during 
initial physical examination and serum was frozen within a few hours of collection and 
stored at -80oC until analysis.  Left-over naturally-passed feces collected for routine 
fecal examination were frozen within a few hours of collection at -80oC, and were stored 
frozen until processing of samples for DNA extraction.  
Healthy control dogs: Ten healthy dogs were enrolled.  All dogs were privately owned, 
lived in diverse home environments, and were fed a variety of commercial diets 
(Supplementary Table 4). All dogs were judged to be healthy on the basis of normal 
clinical examination findings and routine laboratory testing. None of the dogs had 
exhibited clinical signs of GI disease for at least 6 weeks prior to clinical evaluation. 
None of the dogs had received antibiotics or other drug therapy for at least 2 months 
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prior to clinical examination. All dogs were eating a commercial canine maintenance 
diet (Supplementary Table 4). 
Dogs with IBD: Dogs with clinical signs of chronic GI disease (i.e., vomiting, diarrhea, 
anorexia, weight loss, etc.) were diagnosed with idiopathic inflammatory bowel disease 
(IBD) by a board certified veterinary internist (AEJ) based on the World Small Animal 
Veterinary Association (WSAVA) criteria: (i) chronic (i.e., > 3 weeks) GI signs; (ii) 
histopathologic evidence of mucosal infiltration with inflammatory cell; (iii) inability to 
document other causes of GI inflammation; (iv) inadequate response to dietary, 
antibiotic, and anthelmintic therapies, and (v) clinical response to anti-inflammatory or 
immunosuppressive agents. Histological samples were obtained endoscopically. The 
clinical status of each dog was evaluated using a published clinical canine IBD activity 
index (CIBDAI).125 Twelve dogs that showed clinical improvement after therapy were 
enrolled this study. All medications had been discontinued at least 2 weeks prior to the 
first sample collection time point (IBD-PRE). After the first sample collection, dogs 
were then treated with immunosuppressive drug therapy (i.e., prednisone [1-2 mg/kg, 
q24h, PO], prednisolone [1-2 mg/kg, q24h, PO], budesonide [1-3 mg/kg, q24h, PO], 
cyclosporine [3-5 mg/kg, q12h or q24h, PO], or a combination of these), and 5 of 12 
dogs also received the antibiotic metronidazole (10 mg/kg, q12h, PO). A second set of 
serum and fecal samples was obtained from these dogs after 21 days of treatment (IBD-
POST). In addition to medical therapy, all IBD dogs were fed various commercial diets 
(Supplementary Table 5). 
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IV.3.2 DNA extraction 
An aliquot of 100 mg (wet weight) of each fecal sample was extracted by a bead-
beating method using the ZR Fecal DNA KitTM (Zymo Research Corporation, Irvine, 
CA) following the manufacturer’s instructions. The bead-beating step was performed on 
a homogenizer (FastPrep-24, MP Biomedicals, Santa Ana, CA) for 60 s at a speed of 4 
m/s. Fecal DNA was stored at -80°C until analysis. 
 
IV.3.3 454-pyrosequencing 
Bacterial tag-encoded FLX-titanium amplicon pyrosequencing (bTEFAP) based 
the V4-V6 region (E. coli position 530 – 1100) of the 16S rRNA gene was performed to 
evaluate the relative abundances of bacterial taxa with primers forward 530F: 
GTGCCAGCMGCNGCGG and reverse 1100R: GGGTTNCGNTCGTTR. Raw 
sequence data were screened, trimmed, denoised, chimera depleted, and filtered using 
the QIIME pipeline version 1.8.0 (http://qiime.sourceforge.net)127 with the following 
settings: minimum read length of 300 bp; no ambiguous base calls; no homopolymeric 
runs longer than 8 bp; average quality value.q25 within a sliding window of 50 bp. 
Operational taxonomic units (OTUs) were defined as sequences with at least 97% 
similarity using QIIME. For classification of sequences on a genus level the naıve 
Bayesian classifier within the Ribosomal Database Project (RDP, v10.28) was used. The 
confidence threshold in RDP was set to 80%. 
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IV.3.4. Quantitative PCR (qPCR) 
The qPCR assays for selected bacterial groups were performed to validate 
pyrosequencing result and/or to evaluate bacterial groups that are typically present at 
very low abundance or underrepresented in 16S rRNA gene based sequencing (total 
bacteria; Phylum level – Fusobacteria, Bacteroidetes; Family level – Ruminococcaceae; 
Genus level –Bifidobacterium spp., Blautia spp., Faecalibacterium spp., Turicibacter 
spp., and Lactobacillus spp.; and species level – Escherichia coli (E. coli). The qPCR 
cycling, the oligonucleotide sequences of primers and probe, and respective annealing 
temperatures for selected bacterial groups were described previously.8,16 A commercial 
real-time PCR thermal cycler (CFX 96 Touch™ Real-Time PCR Detection System; 
Biorad Laboratories, Hercules, CA) was used for all qPCR assays and all samples were 
run in duplicate fashion. 
IV.3.5 Analysis of serum metabolites  
Untargeted metabolomics analysis was performed by the West Coast 
Metabolomics Center at the University of California (Davis, CA). Serum aliquots were 
extracted by degassed acetonitrile. Internal standards C08-C30 FAMEs were added and 
the samples were derivatized by methoxyamine hydrochloride in pyridine and 
subsequently by N-methyl-N-trimethylsilyltrifluoroacetamide for trimethylsilylation of 
acidic protons. Analytes were separated using an Agilent 6890 gas chromatograph 
(Santa Clara, CA) and mass spectrometry was performed on a Leco Pegasus IV time of 
flight mass spectrometer (St. Joseph, MI) following the published protocol.47 
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IV.3.6 Statistical analysis 
Sequence data and qPCR data: Differences in bacterial abundances between the HC 
and IBD-PRE groups were evaluated using a Mann-Whitney test. Samples collected 
before and after treatment from each IBD dog were compared using a Wilcoxon signed 
rank test. The Benjamini & Hochberg’s False Discovery Rate was used to correct for 
multiple comparisons and an adjusted p < 0.05 (i.e., q < 0.05) was considered to be 
statistically significant. To evaluate differences in overall microbiota composition (i.e., 
beta-diversity) between the groups, the analysis of similarities (ANOSIM) was 
performed on the unweighted UniFrac distance matrixes. The PICRUSt (Phylogenetic 
Investigation of Communities by Reconstruction of Unobserved States: 
http://picrust.github.io/picrust/)128 was used to predict the functional capabilities of 
bacteria based on the 16S rRNA gene dataset.  Linear discriminant analysis (LDA) effect 
size (LEfSe: http://huttenhower.sph.harvard.edu/galaxy/)129 was utilized to evaluate 
differentially abundant bacterial taxa and predicted function between the animal groups. 
To identify associations of microbial abundances with the use of antibiotic and other 
clinical metadata (age, weight, gender), which may be confounding factors, MaAsLin 
(Multivariate Analysis by Linear Models: http://huttenhower.sph.harvard.edu/maaslin)128 
was utilized 
Untargeted metabolomics data: Univariate analysis; Differences in the abundance of 
serum metabolites between the HC and IBD-PRE groups were evaluated using a Mann-
Whitney test. Serum samples collected before and after treatment from each affected dog 
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(IBD-PRE vs. IBD-POST) were compared using a Wilcoxon signed rank test. Univariate 
analysis was performed using Prism version 5 (Graph Pad Software, La Jolla, CA). 
Multivariate analysis; Data were normalized to the sum of the total spectral integral, log 
transformed, mean centered, and divided by the standard deviation of each variable prior 
to multivariate analysis. PCA was performed and a heatmap was generated using 
MetaboAnalyst.130 Correlation and biochemical relationship networks; Correlation 
analyses were performed in R using the “cor” function. Relationships with a Pearson’s 
correlation coefficient greater than 0.9, or smaller than -0.9, were used to build 
correlation networks. For biochemical relationship analysis, named metabolites were 
mapped onto a modified MetaMapp network.24 The network originally published by 
Barupal et al.131 was expanded by the inclusion of additional nodes and edges as 
described by Steelman et al.64 Correlation and biochemical relationship networks were 
visualized in Cytoscape132 by mapping metabolite data onto the expanded MetaMapp 
network. Data included alphanumeric name, level of significance (q > or < 0.25), and 
PubChem ID as the unique identifier. A custom visual style was created using the 
following color scheme: white nodes represent metabolites that were not detected in the 
present study, light blue nodes represent metabolites that were detected but did not differ 
significantly among groups, and dark blue nodes represent metabolites that did differ 
significantly among groups. Evaluation of the performance of potential biomarkers; 
ROC analysis was performed using the Classical Analysis module in ROC Curve 
Explorer & Tester (ROCCET).133 
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IV.4 Results 
The characteristics of the healthy control dogs (HC) and dogs with IBD (pre-
treatment, IBD-PRE; post-treatment, IBD-POST) are summarized in Table 1. Significant 
differences in age and body weight were observed between HC and dogs with IBD. The 
canine IBD activity index (CIBDAI) was significantly decreased after 3 weeks of 
medical therapy (Table 6). 
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Table 6. Dog characteristics   
    HC   IBD-PRE    IBD-POST   
p-value  
(HC vs. IBD-PRE) 
Number   10  12  12  n/a 
Age (years; mean ± SD)  4.2 ±  2.9  7.6 ± 3.6  7.6 ± 3.6  0.025 
Gender (male/female)  5/5  5/7  5/7  1.0 
Weight (kg; median [range])  26.5 [7.0 - 42.0]  5.5 [3.0 - 23.0]  6.5 [3.0 - 23.0]  0.0005 
CIBDAI (median [range])   n/a   6.0 [1.0 - 13.0]   1.0 [0-5.0]   0.0024* 
HC, healthy control dogs; IBD-PRE, dogs with IBD pre-treatment; IBD-POST, dogs with IBD post-treatment; CIBDAI, canine IBD activity 
index * p-value from IBD-PRE vs. IBD-POST 
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IV.4.1 Sequence analysis 
The 454-pyrosequencing pipeline yielded 297,619 quality sequences with an 
average of 8,753 sequences per sample. To account for unequal sequencing depth across 
samples, the subsequent analysis was performed on a randomly selected subset of 2,900 
sequences per sample. The pre-treatment sample from one dog with IBD was excluded 
due to insufficient sequencing depth. A total of 11 phyla and138 genera were identified. 
The sequencing data have been deposited into the Sequence Read Archive (SRA) of the 
National Center for Biotechnology Information (NCBI) under accession number 
SRP040310. 
Fecal microbial communities in healthy control dogs and dogs with IBD: To 
characterize the global differences in fecal microbial communities between groups, a 
principal coordinates analysis (PCoA) was performed on unweighted UniFrac distances. 
The PCoA plots showed significant separation between the fecal samples from the HC 
and IBD-PRE groups (analysis of similarity [ANOSIM]; p = 0.01) (Figure 10A). The 
Shannon index and the Chao 1 metric were significantly decreased in the IBD-PRE 
group compared to the HC group (p = 0.014, 0.0146, respectively; Figure 10C). The 
number of observed species was also decreased in the IBD-PRE group but did not reach 
statistical significance (p = 0.0656; Figures 10B and 10C). Linear discriminant analysis 
(LDA) effect size (LEfSe) was utilized to determine differentially abundant bacterial 
taxa between the animal groups. A total of 22 bacterial groups were differentially 
expressed (α = 0.01, LDA score > 3.0) between the HC and IBD-PRE groups. 
Gammaproteobacteria were overrepresented, while Erysipelotrichia, Clostridia, and  
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Figure 10: Bacterial diversity measures. β diversity: (A) principal coordinates analysis 
(PCoA) of unweighted UniFrac distances of 16S rRNA genes. PCoA plots along with 
Principal Coordinates (PC) 1 and PC 3. Analysis of similarity (ANOSIM) revealed 
clustering between healthy control dogs and dogs with IBD (p = 0.01), but not between 
IBD pre-treatment and IBD post-treatment groups (p = 0.34). Alpha diversity measures: 
(B) rarefaction analysis (number of observed species) of 16S rRNA gene sequences. 
Lines represent the mean of each group, while the error bars represent the standard 
deviations. (C) Comparisons of alpha diversity. Samples from dogs with IBD post-
treatment were divided into two groups based on antibiotic administration status during 
3 weeks of medical intervention. Red lines represent the median for each measure. HC, 
healthy control dogs; IBD-PRE, dogs with IBD pre-treatment; IBD-POST_NON AB, 
dogs with IBD post-treatment that did not receive antibiotic; IBD-POST_AB, dogs with 
IBD post-treatment that received antibiotic *p < 0.05; and **p < 0.01 
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Bacteroidia were underrepresented in dogs with IBD-PRE (Figure 11). Multivariate 
Analysis by Linear Models (MaAsLin) was utilized to identify associations of microbial 
abundances with clinical metadata (age, weight, gender), which may be confounding 
factors. None of these variables were significantly associated with microbial abundance. 
qPCR analysis of fecal microbial communities: qPCR assays for selected bacterial 
groups were performed to confirm pyrosequencing results and/or to quantitate bacterial 
groups that are typically present at very low abundance or underrepresented in 16S 
rRNA gene sequencing data based on the authors’ experience from previous studies (i.e., 
Bifidobacterium spp., Faecalibacterium spp.).14,134,135 The abundances of Blautia spp., 
Faecalibacterium spp., and Turicibacter spp. were significantly decreased in the IBD-
PRE group (q = 0.0277, 0.0480, 0.0380, respectively) compared to those in the HC 
group. E. coli appeared to be increased in the IBD-PRE group, but this increase did not 
reach statistical significance when the p-value was adjusted by False Discovery Rate 
(FDR) of 5% (q = 0.0560; Figure 12).   
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Figure 11: Linear discriminant analysis (LDA) effect size (LEfSe) of 454-
pyrosequencing data sets based on 16S rRNA gene sequences.Taxonomic distribution of 
bacterial groups significant for IBD. A total of 22 differentially abundant bacterial taxa 
were detected (α = 0.01, LDA score > 3.0). Of those, 7 bacterial taxa were significantly 
overrepresented in pretreatment samples from dogs with IBD (green) and 15 bacterial 
taxa were overrepresented in samples from healthy control dogs (red). 
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Figure 12.The abundances of selected bacterial groups in healthy dogs and dogs with 
IBD (pre- and post-treatment) based on qPCR. Samples from dogs with IBD post-
treatment were divided into two groups based on antibiotic administration status during 
the 3 weeks of medical intervention. Red lines represent the median of log DNA. HC, 
healthy control dogs; IBD-PRE, dogs with IBD pre-treatment; IBD-POST_NON AB, 
dogs with IBD post-treatment that did not receive antibiotic; IBD-POST_AB, dogs with 
IBD post-treatment that received antibiotic *q < 0.05 
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Predicted functional composition of fecal microbial communities: To investigate 
alterations in GI microbial function, an analysis for Phylogenetic Investigation of 
Communities by Reconstruction of Unobserved States (PICRUSt) was applied to the 
16S rRNA gene sequencing data. The PICRUSt results (Figure 13A) were then analyzed 
using LEfSe to identify microbial functions that were significantly different in their 
abundance between groups. A total of 4 differentially abundant bacterial functions were 
observed between the HC and IBD-PRE groups (α = 0.01, LDA score > 3.0). Of those, 
the functions of secretion system and transcription factors were overrepresented in the 
IBD-PRE group. In contrast, amino acid metabolism was underrepresented in the IBD-
PRE group (Figure 13B). To investigate the alteration of some of the bacterial functions 
of major metabolic systems, a univariate analysis was applied on the PICRUSt data. The 
relative abundances of lipid, carbohydrate, and energy metabolisms were not 
significantly different between the HC and IBD-PRE groups (Figure 13C). 
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Figure 13: Predicted functional composition of metagenomes based on 16S rRNA gene 
sequencing data. (A) Relative abundances of predicted functions (second level of the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) Ortholog (KO) hierarchy) based 
on phylogenetic investigation of communities by reconstruction of unobserved states 
(PICRUSt) data set. Each stacked bar represents relative abundances of the predicted 
functions of each dog. (B) LEfSe based on the PICRUSt data set (third level of the KO 
hierarchy) revealed a total of 4 differentially enriched bacterial functions (enriched in 
healthy controls: amino acid metabolism, enriched in IBD dogs: secretion system, 
transcription factors, and a pathway with unknown function) between healthy control 
dogs and dogs with IBD (pre-treatment; α = 0.01, LDA score > 3.0). None of the 
bacterial functions were differentially expressed between IBD pre-treatment and IBD 
post-treatment. (C) Univariate analysis of major metabolisms. Red lines represent the 
median of relative abundance. HC, healthy control dogs; IBD-PRE, dogs with IBD pre-
treatment; IBD-POST, dogs with IBD post-treatment; NS, no significance *metabolic 
functions that differed significantly between healthy control dogs and dogs with IBD 
**q < 0.01. 
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Effects of medical treatment on fecal microbial communities: We further evaluated 
the effects of 3 weeks of medical intervention on fecal microbial communities in dogs 
with IBD. All dogs received a standard therapy, which consisted of administration of an 
immunosuppressive drug (i.e., prednisone [1-2 mg/kg, q24h, PO], prednisolone [1-2 
mg/kg, q24h, PO], budesonide [1-3 mg/kg, q24h, PO], cyclosporine [3-5 mg/kg, q12h or 
q24h, PO], or a combination of these) and feeding of an elimination diet (i.e., antigen-
restricted or protein hydrolysate diets).  
Five out of twelve IBD dogs received the antibiotic metronidazole (10 mg/kg, 
q12h, PO) in addition to immunosuppressive drug therapy. All dogs responded to their 
therapies (i.e., GI signs resolved, CIBDAI improved) and none had diarrhea after 
medical intervention. Although all dogs showed clinical improvement after 3 weeks of 
therapy, no major differences in microbial communities were observed between the 
IBD-PRE and IBD-POST groups (ANOSIM, p = 0.34; Figure 10A). In the IBD-POST 
group, the diversity indices further decreased compared to the IBD-PRE, but this 
decrease did not reach statistical significance (Figures 10B and 10C). The LEfSe 
analysis revealed that none of the bacterial taxa were differentially expressed between 
IBD-PRE and IBD-POST groups. These observations were confirmed by the qPCR 
assays, as none of the abundances of the evaluated bacterial groups were significantly 
different between IBD-PRE and IBD-POST (Figure 12). Consequently, none of the 
predicted bacterial functions were differently expressed between IBD-PRE and IBD-
POST.  
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To address if the administration of metronidazole had a confounding effect on 
the GI microbiota in this study, the sequencing data within the IBD-POST group was 
compared between dogs that received antibiotic versus dogs that did not receive 
antibiotic. The PCoA plots showed no significant separation between the samples from 
dogs that received antibiotic and those that did not (ANOSIM, p = 0.51; Figure 14A). 
Also, there were no significant differences in unweighted UniFrac distances between the 
pre- and post-treatment samples from dogs that received antibiotic and those that did not 
(p = 0.5273; Figure 14B). The results of the qPCR assays were also statistically analyzed 
in the IBD-POST group based on antibiotic administration. Noteworthy trends were 
observed, suggesting that dogs that did not receive antibiotic in general had median 
abundances of Fusobacteria, Bacteroidetes, Ruminococcaceae, Bifidobacterium spp., 
Blautia spp., Faecalibacterium spp., and E. coli that were more similar to median 
abundances observed in the HC group (Figure 12). This was most notable for 
Turicibacter spp., where dogs that had received antibiotic had significantly decreased 
abundances of this bacterial group compared to dogs of the HC group. MaAsLin was 
utilized to identify associations of microbial abundance with antibiotic treatment. No 
significant association between antibiotic treatment and microbial abundance was 
identified. 
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Figure 14. Effect of antibiotic administration on the fecal microbiota. (A) PCoA of 
unweighted UniFrac distances of 16S rRNA genes from dogs with IBD pre-treatment 
and post-treatment. Dogs in the IBD post-treatment group were divided into two groups 
based on the antibiotic administration status during 3 weeks of medical intervention. 
ANOSIM revealed no clustering either between IBD-PRE and IBD-POST_AB, or IBD-
PRE and IBD POST-NON_AB (ANOSIM p = 0.26, p = 0.51, respectively). Dashed 
lines connect the pre-treatment and the post-treatment samples from each dog. The pre-
treatment sample from one dog with IBD was excluded due to insufficient sequencing 
depth. (B) Median unweighted UniFrac distance between pre- and post-treatment 
samples from dogs with and without antibiotic treatment. Whiskers represent 
interquartile ranges. IBD-PRE, dogs with IBD pre-treatment; IBD-POST_NON AB, 
dogs with IBD post-treatment that did not receive antibiotic; IBD-POST_AB, dogs with 
IBD post-treatment that received antibiotic; NS, no significance 
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IV.4.2 Untargeted metabolomics analysis 
A total of 359 metabolites were detected. Of those, 157 were identified 
metabolites, while 202 lacked full structural identification (unknown metabolites). These 
unknown metabolites are listed by their Binbase identification numbers 
(http://fiehnlab.ucdavis.edu/projects/binbase_setupx).136  
Serum metabolite profiles in healthy control dogs and dogs with IBD: To 
characterize the global metabolic differences between groups, a principal component 
analysis (PCA) was applied. Serum metabolite profiles associated with the HC group 
were tightly clustered, whereas those in the IBD-PRE group were much more scattered 
(Figure 15A). There was considerable overlap in metabolite profiles observed between 
the two IBD groups. Similarly to the results of the PCA analysis, no distinct pattern was 
observed when the data were plotted by heatmap analysis (Figure 15B). However, two 
major groups of metabolites clustered in the dendrogram, with cluster 1 being more 
abundant in healthy animals and cluster 2 appearing to be more abundant in the IBD 
group. Although many unknown metabolites are included on this heatmap, cluster 1 
contains a number of amino acids, whereas cluster 2 is composed of a wide variety of 
metabolites. Nonparametric univariate analysis using FDR of 5% revealed a total of 9 
metabolites (4 identified and 5 unknown) that differed significantly between the HC and 
IBD-PRE groups. Identified metabolites are shown at the top of Table 7 and in Figure 
15C. Complete statistical results for all metabolites with FDR less than 25% are shown 
in supplementary Table 1. The 4 identified metabolites include gluconic acid lactone 
(also known as gluconolactone), hexuronic acid (also known as ascorbic acid or vitamin 
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C), 3-hydroxybutanoic acid (ketone body) and ribose. All 4 metabolites were 
significantly increased in the IBD-PRE group (Figure 15C). 
Effects of medical treatment on serum metabolite profiles: Three metabolites 
differed significantly between the IBD-PRE and IBD-POST groups. Of these, only one, 
gluconic acid lactone, was an identified metabolite (Figure 15C and supplementary 
Table 1). As performed in the analysis of fecal microbial communities, serum metabolite 
profiles were also evaluated based on antibiotic administration. The PCA plot showed no 
clear separation between samples from dogs that received antibiotic and those that did 
not (Figure 16). The univariate analysis of the selected metabolites based on antibiotic 
administration status also revealed no significant differences in any of the significantly 
different metabolites between samples from dogs that received antibiotic and those that 
did not (Figure 15C).  
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Figure 15. Serum metabolite profiles. (A) PCA score plots of metabolites in serum from 
healthy control dogs, dogs with IBD pre-treatment, and dogs with IBD post-treatment. 
Ellipses represent the 95% confidence interval of metabolite profiles for each group. No 
clear separations between groups were identified. (B) Hierarchical clustering and 
heatmap of the top 75 metabolites that were different in their peak intensity between 
groups. The 75 most abundant metabolites are provided on the x-axis (see detail in 
supplementary table 3). Each row represents the serum metabolite profile of each dog 
and sorted by group (colored bars on the x-axis represent groups (blue, healthy control 
dogs; red, dogs with IBD post-treatment; green, dogs with IBD pre-treatment) (C) 
Comparisons of the peak intensity for differentially expressed serum metabolites. 
Samples from dogs with IBD post-treatment were divided into two groups based on 
antibiotic administration status during 3 weeks of medical intervention. Gluconic acid 
lactone was the only identified metabolite that differed significantly between dogs with 
IBD pre-treatment and post-treatment. Red lines represent the median of peak intensity. 
HC, healthy control dogs; IBD-PRE, dogs with IBD pre-treatment; IBD-POST_NON 
AB, dogs with IBD post-treatment that did not receive antibiotic; IBD-POST_AB, dogs 
with IBD post-treatment that received antibiotic *q < 0.05 
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Table 7. Identified metabolites with altered peak intensity (q < 0.25) between healthy 
control dogs and dogs with IBD 
Metabolite  HC  IBD-PRE Fold 
change 
p value q value 
 Median Range  Median Range (IBD-
PRE/HC) 
gluconic acid lactone  285 (232 - 479)  723 (303 - 22,194) 14.7 3.71E-05 0.0060 
hexuronic acid  1,454 (898 - 1,715)  2,206 (1,456 - 8,107) 2.1 5.88E-05 0.0063 
3-hydroxybutanoic acid  3,437 (2,169 - 5,488)  7,970 (4,058 - 37,369) 3.6 9.28E-05 0.0075 
ribose  1,174 (507 - 1,831)  2,180 (1,299 - 5,449) 2.2 0.0004 0.0198 
aminomalonic acid  6,922 (5,936 - 9,857)  4,739 (1,756 - 9,807) 0.7 0.0034 0.0740 
2-hydroxybutanoic acid  14,612 (9,599 – 44,161)  35,109 (16,902 - 64,067) 2.0 0.0044 0.0894 
tryptophan  160,468 (144,526 - 308,348)  113,443 (26,157 - 209,607) 0.7 0.0056 0.0912 
fucose+ rhamnose  1,133 (953 - 1,423)  1,753 (747 - 2,737) 1.5 0.0056 0.0912 
tyrosine  101,389 (74,276 - 179,264)  64,785 (29,729 - 110,404) 0.6 0.0071 0.0923 
cellobiotol  197 (102 - 420)  305 (140 - 1,505) 2.4 0.0071 0.0923 
5-methoxytryptamine  1,600 (694 - 3,513)  3,959 (1,132 - 9,964) 2.3 0.0071 0.0923 
cysteine  1,069 (570 - 1,769)  2,125 (545 - 7,414) 2.6 0.0090 0.1072 
2-deoxyerythritol NIST  3,310 (2,386 - 4,314)  4,986 (2,584 - 15,227) 2.0 0.0090 0.1072 
xylitol  638 (385 - 958)  1,161 (540 - 7,440) 2.7 0.0112 0.1287 
xylose  1,801 (213 - 2,488)  2,475 (1,587 - 4,188) 1.6 0.0138 0.1435 
nicotinic acid  191 (143 - 311)  343 (126 - 755) 2.0 0.0169 0.1654 
erythritol  1,018 (778 - 1,470)  1,305 (881 - 4,254) 1.7 0.0206 0.1847 
uracil  1,532 (1,022 - 2,733)  2,301 (1,170 - 3,724) 1.4 0.0249 0.2012 
p-hydroquinone  3,718 (180 - 12,373)  578 (317 - 25,634) 0.6 0.0300 0.2151 
homovanillic +                 
4-hydroxymandelic acid 
 2,855 (1,485 - 4,014)  1,878 (1,291 - 3,198) 0.7 0.0300 0.2151 
trans-4-hydroxyproline  7,975 (2,673 - 14,850)  2,753 (713 - 11,264) 0.6 0.0358 0.2411 
citric acid  85,176 (54,525 - 107,022)  124,882 (29,957 - 363,887) 1.8 0.0358 0.2411 
xanthine  954 (504 - 1,665)  1,130 (155 - 2,321) 1.3 0.0426 0.2412 
threonic acid  2,973 (1,750 - 4,658)  4,880 (1,479 - 15,737) 2.1 0.0426 0.2412 
HC, healthy control dogs; IBD-PRE, dogs with IBD pre-treatment 
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Figure 16. Principal component analysis (PCA) score plots of serum metabolomics data 
from dogs with IBD pre-treatment, dogs with IBD post-treatment that received 
antibiotic, and dogs with IBD post-treatment that did not received antibiotic. Ellipses 
represent the 95% confidence interval of the metabolite profile of each group. No clear 
separations between groups were identified. IBD-PRE, dogs with IBD pre-treatment; 
IBD-POST_NON AB, dogs with IBD post-treatment that did not receive antibiotic; 
IBD-POST_AB, dogs with IBD post-treatment that received antibiotic 
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Evaluation of the performance of potential biomarkers: To evaluate the utility of the 
differentially abundant metabolites as potential biomarkers, we conducted a receiver 
operating characteristic (ROC) analysis. All metabolites, both identified and unknown, 
as well as metabolite ratios, were screened for their ability to discriminate between the 
HC and IBD-PRE groups using ROCCET (ROC Curve Explorer & Tester, 
http://www.roccet.ca).133 Complete results for all metabolites with area under the curve 
(AUC) greater than 0.75 are shown in Supplementary Table 2. Gluconic acid lactone had 
the highest discrimination ability among 157 identified metabolites. With an optimal cut-
off peak intensity value of 497, gluconic acid lactone could be used to differentiate 
between the HC and IBD-PRE groups with 91.67% sensitivity and 100% specificity 
(Figure 17A). It could also be used discriminate between the IBD-PRE and IBD-POST 
groups with 75.0% sensitivity and 91.67% specificity at a cutoff value of 495 (Figure 
17B).   
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Figure 17. Receiver operating characteristic (ROC) analysis for gluconic acid lactone. 
(A) Discrimination ability between healthy control dogs and dogs with IBD. (B) 
Discrimination ability between dogs with IBD pre- and post-treatment. AUC, area under 
the curve 
 
 
 
Metabolite set enrichment analysis: The pentose phosphate pathway was significantly 
enriched (q = 0.0012) in the IBD-PRE group compared to the HC group. Catecholamine 
biosynthesis (enriched in HC) and nicotinate and nicotinamide metabolism (enriched in 
IBD-PRE) were also differentially expressed, but did not differ statistically when p-
values were adjusted by FDR of 5% (q = 0.1288, 0.1602, respectively). No significantly 
enriched pathways were observed between the IBD-PRE and IBD-POST groups.  
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Network analysis: Due to the low number of identified metabolites that were 
significantly different between groups using an FDR of 5%, we used an FDR of 25% 
(roughly corresponding to p < 0.05) in order to evaluate the biochemical relationships 
among the metabolites. This resulted in a set of 33 identified metabolites that were 
differentially abundant between groups.   A total of 120 metabolites, 20 of which 
differed significantly between groups, were mapped to a modified MetaMapp 
network,64,131 which included 1,070 relationships among 293 metabolites (Figure 18A). 
In this network, nodes represent metabolites and edges denote relationships within a 
biochemical pathway. Differentially abundant metabolites were distributed throughout 
the network and none were directly connected to each other, except for trans-4-
hydroxyproline and proline. Both of these metabolites were reduced in IBD animals, 
which could be reflective of the increased turnover of collagen often seen in IBD and a 
depletion of the substrates required for its synthesis. Creation of a sub-network using 
only metabolites identified in the present study as well as first neighbors showed a group 
of amino acids that clustered around glutamic acid (Figure 18B), suggesting a central 
role for glutamic acid or its associated pathways in IBD. 
Correlation analysis: We next explored the metabolic networks associated with each 
group using a correlation analysis. Metabolites in equilibrium are positively correlated; 
the loss or gain of correlations thus suggests an alteration in the flow of substrates 
through a given pathway. The IBD groups had two clusters of correlated metabolites. 
One of the clusters, highlighted in green in Figure 19, was centered around citric acid 
and its metabolites (Figures 19B and 19C). The second cluster, highlighted in blue in 
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Figure 10, was composed of saturated, monounsaturated, and polyunsaturated fatty acids 
(Figure 10). No relationships between biochemical pathways were identified for either 
cluster using network analysis. In the healthy group, there was only one minor cluster 
which was composed of fatty acids (Figure 19A).   
 
 
 
 
Figure 18. Network analysis of serum metabolites. (A) Overview of the network of relationships 
among metabolites. (B) Clustered network detected by network analysis. White nodes indicate 
metabolites that were not detected in this study, light blue nodes indicate metabolites that were 
detected but were not different (q > 0.25) between groups, dark blue nodes indicate metabolites that 
were detected and were different among groups. The edges indicate biochemical relationship among 
the metabolites. 
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Figure 19. Correlation analysis of serum metabolites. Metabolic networks associated 
with (A) healthy control dogs, (B) dogs with IBD pre-treatment, and (C) dogs with IBD 
post-treatment. The IBD groups had two clusters of correlated metabolites. One of the 
clusters, highlighted in green, was centered around citric acid and its metabolites. The 
second cluster, highlighted in blue, was composed of saturated, monounsaturated, and 
polyunsaturated fatty acids. The healthy group had only one minor cluster which was 
composed of fatty acids. 
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IV.5 Discussion 
In this study, we applied a dual-omics approach to improve our current 
understanding of the pathogenesis of canine IBD, the host-microbial interactions, and the 
functional aspects of the canine GI microbiota. Microbiota analysis revealed significant 
differences in fecal microbial communities between dogs with IBD and healthy dogs, 
and also significantly decreased alpha-diversity indices in dogs with IBD. On higher 
phylogenetic levels, the major differences were decreases in Bacteroidetes and various 
taxa within Firmicutes and concurrent increases in Proteobacteria in dogs with IBD.  
Similar compositional shifts have also been observed in intestinal biopsies and/or fecal 
samples from human IBD patients. 137–140 In this study, the increased abundance of 
Gammaproteobacteria was mainly due to increases in Enterobacteriaceae. The qPCR 
results suggested that this increase was due to E. coli, and this group is of particular 
interest, as previous studies have reported an increased virulent potential of E. coli, such 
as adhesive capacity, invasive capacity, toxin production, and inflammatory cytokine 
stimulation, in human patients with IBD.141,142 Adherent and invasive E. coli strains have 
been reported specifically in Boxer dogs with granulomatous colitis.143 Whether the 
virulent potential of E. coli plays a similar role in other forms of canine inflammatory 
bowel disease remains to be determined. Various members of the Firmicutes (Blautia 
spp., Faecalibacterium spp., and Turicibacter spp.) were decreased in IBD. Most of 
these bacterial groups belong to Clostridium clusters IV and XIVa and are believed to be 
major producers of short chain fatty acids (SCFA) and various other metabolites. 
Therefore, a decrease in these groups may have a significant effect on the host health. 
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These differences are similar to those of previous studies evaluating the GI microbiota in 
duodenal mucosal/luminal content and feces in dogs with IBD.4,12,16,28,29,33 
 Based on PICRUSt analysis, the relative abundances of genes associated with a 
given pathway may indicate an increased metabolic capacity of the GI microbiota with 
regard to that pathway. Inferences of the functional gene content were grouped by 
function according to the three-level Kyoto Encyclopedia of Genes and Genomes 
(KEGG) Ortholog (KO) hierarchy and compared using LEfSe with the significance 
threshold set at α of 0.01 and a LDA score of 3.0. In dogs with IBD, the pathways for 
secretion system and transcription factors were overrepresented. This may reflect the 
activation of bacterial defense mechanisms responding to the change in intestinal 
environmental conditions such as availability of nutrients, which may lead to a 
competitive advantage/disadvantage for microbial communities. Pathways representing 
amino acid metabolism were, on the other hand, significantly underrepresented in IBD. 
It has been suggested that commensal microbiota play an important role in the 
extraction, regulation of absorption, or synthesis of some amino acids.144 Recently, an 
association between intestinal dysbiosis and protein energy malnutrition (e.g., 
kwashiorkor disease) has been reported.145 In this study, the metabolomics data also 
suggested alterations in amino acid metabolism and this might be, in part, affected by 
metabolic dysfunction of bacteria. No other pathways were significantly differently 
expressed between healthy control dogs and dogs with IBD. This was surprising for 
carbohydrate metabolism, as many of the decreased bacterial taxa in dogs with IBD are 
associated with the production of SCFA from carbohydrates. Faecalibacterium spp., one 
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of the main butyrate producing bacteria,146 are prominent members of the canine GI 
microbiome.15 Therefore, it was surprising that the carbohydrate metabolism did not 
differ between groups. A limitation of this study was that we used a prediction model 
based on 16S rRNA genes rather than a true metagenomic approach with shot gun 
sequencing of fecal DNA. Future studies are warranted to evaluate functional properties 
of the canine microbiota in more detail in canine IBD. 
The untargeted metabolomic approach brought new insights in regards to 
metabolic differences in canine IBD. Gluconic acid lactone is an oxidized derivative of 
glucose and is capable of scavenging free radicals. Hexuronic acid is a biologically 
active form of vitamin C and considered an antioxidant due to its ability to donate 
electrons. 3-hydroxybutanoic acid is a ketone body, and increased synthesis of this 
metabolite reflects an energy insufficiency. Ribose is vital for biological systems and an 
important source for further metabolism. These findings are somewhat different than 
those in human IBD studies which have shown altered, for the most part, lipid and amino 
acid metabolism.42 One of the potential explanations is that most of the studies in human 
IBD applied nuclear magnetic resonance spectroscopy. We, on the other hand, applied 
GC-TOF/MS which may not be sensitive enough for lipid molecules. Therefore, the 
difference in the analytical method can contribute to the observed differences.  
Metabolomics is a relatively new field and still at a descriptive stage even in the study of 
human IBD. Therefore, large scale multi-center studies in both human and canine IBD 
are needed to address this species differences. Although gluconic acid lactone showed 
high discrimination ability for disease status, this may simply reflect inflammation status 
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and may not be specific for IBD. Therefore, further studies that evaluate specific 
metabolites in different disease cohorts will be useful to see if those can be useful non-
invasive maker for IBD.   However, gluconic acid lactone has a possible utility as a 
biomarker for treatment efficacy. The enrichment analysis indicated that the pentose 
phosphate pathway was more activate in IBD, mainly due to increased abundance of 
gluconic acid lactone and ribose.  The pentose phosphate pathway is an alternative to 
glycolysis and a critical pathway in cell redox balance and proliferation. This pathway 
produces NADPH, ribose, and energy sources for further metabolism and is required for 
glutathione reduction. Therefore, this pathway has an important role in the protection 
from oxidative stress and DNA/RNA synthesis.147 These metabolic alterations may 
suggest the presence of oxidative stress. This is further supported by the decreased 
abundance of aminomalonic acid, and the increased abundances of 2-hydroxybutanoic 
acid and cysteine in dogs with IBD, although the differences of these metabolites did not 
reach statistical significance set at FDR of 5%. Taken all together, these results suggest 
that dogs with IBD are affected by oxidative stress due to their state of inflammation, 
and additional therapeutic interventions aimed towards mitigating oxidative stress could 
be beneficial. The association between the alteration of GI microbial communities and 
the presence of oxidative stress in GI tract has also been reported in human IBD patients, 
and E. coli seems to gain competitive advantage in an oxidative stress environment.128,148 
To validate this hypothesis, large scale studies with different treatment regimens (e.g., 
traditional standard therapy vs. additional antioxidant drug intervention) evaluating the 
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difference in the abundance of antioxidants and byproducts of oxidative stress related 
metabolism (e.g., gluconic acid lactone) are needed.  
We also evaluated the effects of 3 weeks of medical treatment on both the GI 
microbial and serum metabolite profiles. Although all dogs with IBD in this study 
showed clinical improvement, this did not correlate with recovery from dysbiosis. This 
suggests an ongoing pathological process. Therefore, these dogs may need more time to 
recover and/or additional therapy such as antioxidant supplementation, and these dogs 
may have a potential risk of relapse of clinical signs. However, administration of 
metronidazole may also contribute to this inconsistency in some extent. Antibiotics have 
been shown to be a strong driver to shift GI microbial composition.128 In this study, the 
qPCR assays suggested that antibiotic administration might delay a recovery from the 
dysbiosis, as those dogs that did not receive antibiotic had median abundances of 
bacterial groups more similar to those of healthy dogs. A recent large multicenter study 
also observed similar effects of antibiotics on human Crohn’s disease patients, and the 
authors hypothesized that the use of antibiotics has the potential to impact the overall GI 
microbial community and increase the potential for exposure to dysbiosis.149 Studies also 
reported different effects on the composition of the microbiome with different 
antibiotics. A study reported increased abundances of Actinobacteria and Bacteroidetes 
after metronidazole treatment in an model of  experimental colitis.150 While this was not 
the case in our study, we observed similar effects as observed in a study reporting the 
relative resistance of Bifidobacterium spp. to metronidazole.151 Limited information is 
available with regards to the effect of antibiotics on dogs with IBD, although one study 
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evaluating the effects of single and combination drug regimens showed that oral 
prednisone monotherapy is as effective as combination therapy with  prednisone and 
metronidazole for treatment of dogs with IBD.126 An increased susceptibility to 
pathogens and bacterial community shifts (abundance change and functional change) 
were observed by administration of antibiotics in a rodent model of intestinal 
inflammation.48 These results may suggest potential negative effects of indiscriminate 
administration of antibiotics on the intestinal microbiota. The effect of antibiotics on the 
clinical outcome itself requires further studies, as in one study, there was no clear benefit 
of adding metronidazole to treatment regimens, but there was also no disadvantage.126 In 
our study, all 5 dogs that received metronidazole showed clinical improvement. 
Metronidazole treatment was initiated at the time of diagnosis in 4 of 5 dogs due to 
clinician’s preference. Therefore, it remains unknown whether this improvement was 
achieved by the effect of the drug combination, or achieved solely by the effect of the 
immunosuppressive drug. In one dog, metronidazole was added later to the treatment 
regimen due to an incomplete response to immunosuppressive mono-therapy. Although, 
this dog showed improvement, we cannot verify whether the improvement was achieved 
by antimicrobial activity of metronidazole independent of their immunomodulatory 
effects. Consequently, further studies are needed to correlate changes in microbial 
communities and clinical outcome of patients, especially when antibiotics are 
administered.  
Similarly to the effects on the GI microbial communities, antibiotic intervention 
did not significantly affect the serum metabolite profiles. However, in contrast to their 
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effects on the GI microbiota, dogs that received antibiotic had median abundances of 
differentially expressed metabolites that were more similar to median abundances 
observed in healthy dogs. This may potentially be due to an immunomodulatory effect of 
metronidazole. These data suggest that more extensive studies are needed to study the 
impact of antibiotics in canine IBD.   
There are limitations to this study that need to be addressed. Firstly, the small 
sample size of animals used in this study limited the statistical power. Therefore, we 
may have missed some differences in bacterial and metabolite profiles between animal 
groups, especially when evaluating the effects of differences in treatment (i.e., use of 
antibiotic). Secondly, this study was conducted at only one institution and no 
standardization of diet and environment was conducted. However this study cohort 
represents the patients commonly seen in clinical veterinary practice. Moreover, the 
PCA and PCoA plots showed that healthy control dogs were tightly clustered, even 
though their diets varied more than the diets fed to dogs with IBD. This suggests that the 
dietary effects were not a confounding factor in this study. Similar findings were also 
observed in a previous study.12 Finally, we did not have matching control dogs.  In this 
study cohort, there were significant differences in body weight and age between the 
healthy control group and dogs with IBD. The evaluation of GI microbial communities 
using the UniFrac distance matric did not indicate any clustering based on body weight 
and age in this and previous studies.12,16 Furthermore, the multivariate statistical analysis 
also did not identify any associations of microbial abundances and these variables. 
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Therefore, these significant differences in age and body weight may not be a major bias 
in this study. 
In conclusion, this study demonstrates intestinal dysbiosis and altered serum 
metabolite profiles in dogs with IBD. These alterations may suggest the presence of 
oxidative stress and functional alteration of GI microbiota in dogs with IBD. Ongoing 
dysbiosis and bacterial dysfunction were suspected to exist in dogs with IBD even after 
clinical improvement.  Due to the small sample size, further large, multicenter studies 
are needed to validate these findings. 
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CHAPTER V 
CONCLUSIONS 
 
A number of recent studies have emphasized the importance of balanced GI 
microbial communities for GI health in humans and animal models of intestinal 
inflammation.47–49,110 However, there are relatively few clinical studies evaluating the GI 
microbiota in dogs with GI disease. Understanding changes of the microbiota together 
with their associated functional alterations may provide new insights into the 
pathogenesis of GI diseases in dogs and may lay the foundation for future studies aiming 
to develop new therapeutic approaches and biomarkers. Thus, this study was aimed to 
investigate the microbial composition, the relationship between commensal bacteria and 
enteropathogens, and the functional aspects of an altered intestinal microbiota in dogs 
with GI disease.  
Significant alterations of the intestinal structure of microbiota were observed in 
dogs with GI disease throughout our studies. Commonly observed alterations were 
decreases in Ruminococcaceae, Faecalibacterium spp., Turicibacter spp., and Blautia 
spp., with concurrent increases in Proteobacteria, specifically E. coli. These patterns 
observed are consistent with those from previous studies showing significant changes in 
abundances of several bacterial groups in dogs with GI disease.12,16 In addition, the 
current data indicated a reduction in microbial diversity in dogs with IBD. Most of the 
bacterial groups that were decreased in dogs with GI disease belong to Clostridium 
clusters IV and XIVa and are believed to be major producers of SCFA and various other 
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metabolites. Therefore, a decrease in population of these groups (i.e., normal protective 
microbiota) can potentially exacerbate intestinal inflammation.  
 Recent data suggest that the composition of intestinal microbiota and its 
associated metabolites are important factors for the activation of virulence of 
enteropathogens, and also suggest the presence of an important cross-talk between 
commensals and enteropathogens.47,110 Therefore, one goal of this study was to describe 
the relationship between dysbiosis and the presence of the potential enteric pathogen C. 
perfringens, as this organism is deemed to be responsible for several types of diarrhea in 
dogs. 
We observed an association between an increased abundance of C. perfringens, 
and more specifically an increased abundance of enterotoxigenic C. perfringens, and the 
presence of dysbiosis, with the latter manifested as a reduction of several commensal 
bacterial groups in dogs with GI disease.  Furthermore, there was a strong association 
between the presence of CPE and GI disease. However, CPE was only detected in a 
small proportion of fecal samples from dogs that were positive for enterotoxigenic C. 
perfringens, and the presence of enterotoxigenic strains was not always indicative of the 
presence of diarrhea. Also, the increase in the population of enterotoxigenic C. 
perfringens was accompanied with an increase in the population of non-enterotoxigenic 
C. perfringens. This finding led to the conclusion that the increased abundance of C. 
perfringens and enterotoxigenic C. perfringens may be part of an intestinal dysbiosis as 
an effect of disease and may not necessarily play a primary pathological role in the GI 
disease in most dogs. 
 102 
 
However, it may also be possible that an initial dysbiosis due to various causes 
and subsequent changes in bacterial metabolite profiles within the intestinal lumen may 
trigger the production of CPE from enterotoxigenic C. perfringens, as has been 
demonstrated with C. difficile. Further studies evaluating the activity of transcription of 
CPE with concurrent evaluation of metabolite profiles in the luminal content can provide 
more information about the pathogenesis of C. perfringens associated diarrhea. Clearly, 
the relationships between enteropathogens, fecal altered microbial communities, and 
altered bacterial metabolite profiles deserve further studies in dogs with GI disease.   
To describe functional aspects of the intestinal microbiota in dog withy GI 
disease, we analyzed the fecal concentrations of SCFAs in healthy dogs and dogs with 
chronic GI disease. Our findings clearly showed alterations of fecal SCFA 
concentrations that were associated with altered microbial compositions in dogs with 
chronic GI disease. Similar to our findings, studies in humans and rodent models have 
shown that decreased concentrations of SCFAs in the intestinal tract are associated with 
GI diseases such IBD and colorectal cancer.93,152 In these studies, the protective and 
therapeutic effects of SCFAs on GI disease have also been reported. Therefore, further 
studies to evaluate whether interventions aimed at manipulating SCFA concentrations 
within the GI tract may be useful to ameliorate intestinal inflammation and to restore 
proper immune responses are warranted.  
The untargeted metabolomics approach used in this study brought new insights 
in regards to metabolic alterations in dogs with IBD. We identified several serum 
metabolites that were differentially expressed between healthy control dogs and dogs 
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with IBD, and these differences in the metabolite profile revealed potential underlying 
biochemical changes that occur in dogs with IBD. To validate our results, further studies 
should be undertaken. The development and validation of analytical assays for candidate 
metabolites are necessary because the untargeted approach does not provide quantitative 
data, and there may be a profile bias due to the analytical methods being used. In 
addition, the stability of each metabolite has not been reported, and it is challenging to 
find storage conditions that are optimal for all metabolites measured during an 
untargeted exam. Therefore, assay validation by using a targeted approach is necessary 
to demonstrate that these profile changes were indeed associated with the disease, and 
were not due to artificial effects and/or confounding factors. 
The findings from the metabolomics part of study suggest that measuring 
metabolites in dogs with IBD may be useful for further studies. Because this approach is 
a relatively new research field even in the study of human IBD, large scale studies in 
both humans and dogs with IBD are needed to evaluate any potential clinical usefulness 
of some of the metabolites evaluated.  
In the last part of study, we evaluated the effects of 3 weeks of medical treatment 
on both the GI microbiota and serum metabolite profiles in dogs with IBD. The findings 
from this part of study were particularly interesting. While all dogs with IBD showed 
clinical improvement in this study, this did not correlate with recovery from dysbiosis 
and metabolic alterations. This suggests the presence of an ongoing pathological process 
despite clinical improvement. Therefore, these dogs may require more time to recover 
and/or additional therapies, and these dogs may have a potential risk for relapse of 
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clinical signs. Our findings also suggest the necessity for additional biomarkers that are 
able to reflect underling disease processes and the potential risk of clinical recurrence. 
Due to the nature of clinical studies in patients with spontaneous diseases, we 
faced several limitations. In each study, there were significant differences in some 
parameters of patient signalment (e.g., age). Moreover, the subject animals were living 
in different environments and were fed a variety of diets. As for the diseased animals, 
most of the samples were collected at different institutions, and the timing of sample 
collection after the onset of diarrhea varied for patients. Also, we could not evaluate the 
impact of antibiotic administration on our findings, as a variety of treatment regimens 
were applied to the dogs at the discretion of the primary care veterinarian. Nonetheless, 
our findings (e.g., changes in the microbiota) were consistent among the studies 
performed and were also consistent with other previous studies. This may suggest that 
the effects of the pathogenic process on the GI microbiota outweigh those potential 
cofounding factors. However, further longitudinal studies with a standardized protocol 
are still needed to validate these findings by eliminating the potential effects of 
confounding factors. 
In conclusion, the findings of these studies provided new insights into the 
pathogenesis of GI diseases in dogs. Moreover, the study identified potential biomarkers 
for IBD. These findings highlight the importance of balanced microbial communities for 
canine GI health and may lay the foundation for future large-scale clinical studies, which 
ultimately have the potential to improve the quality of life in dogs with GI disease. 
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APPENDIX 
 
Supplementary table 1. Metabolites with altered peak intensity (q < 0.25) between 
groups 
                    
HC vs. IBD-PRE  IBD-PRE vs. IBD-POST 
Metabolite  p value  q value  Metabolite  p value  q value 
362092  3.09E-06  0.000999  506977  2.22E-05  0.007167 
gluconic acid lactone  3.71E-05  0.005994  gluconic acid lactone  2.01E-04  0.021659 
hexuronic acid  5.88E-05  0.006327  224551  2.01E-04  0.021659 
3-hydroxybutanoic acid  9.28E-05  0.007493  309730  0.001433  0.092547 
225396  3.00E-04  0.019381  213961  0.001433  0.092547 
ribose  4.30E-04  0.019837  208381  0.00183  0.098503 
208655  4.30E-04  0.019837  xylitol  0.003637  0.1678 
672987  8.32E-04  0.029859  362056   0.004513   0.18221 
281216  8.32E-04  0.029859  
Unknown metabolites are listed by Binbase identification 
numbers  
200547  0.0020135  0.054196       
213961  0.0020135  0.054196       
438106  0.0020135  0.054196       
225262  0.0026475  0.061082       
314770  0.0026475  0.061082       
aminomalonic acid  0.0034362  0.073993       
2-hydroxybutanoic acid  0.004429  0.089411       
tryptophan  0.0056445  0.091159       
fucose+ rhamnose  0.0056445  0.091159       
212274  0.0056445  0.091159       
210286  0.0056445  0.091159       
tyrosine  0.0071446  0.092308       
cellobiotol  0.0071446  0.092308       
5-methoxytryptamine  0.0071446  0.092308       
367978  0.0071446  0.092308       
307909  0.0071446  0.092308       
cysteine  0.008957  0.10715       
2-deoxyerythritol NIST  0.008957  0.10715       
xylitol  0.011153  0.12866       
xylose  0.01377  0.14347       
235449  0.01377  0.14347       
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Supplementary table 1. Continued        
HC vs. IBD-PRE       
Metabolite  p value  q value       
350396  0.01377  0.14347       
nicotinic acid  0.0169  0.16541       
508772  0.0169  0.16541       
erythritol  0.02058  0.18465       
208381  0.02058  0.18465       
362075  0.02058  0.18465       
uracil  0.024916  0.2012       
460930  0.024916  0.2012       
267647  0.024916  0.2012       
199802  0.024916  0.2012       
p-hydroquinone  0.029961  0.21505       
homovanillic + 4-
hydroxymandelic acid  0.029961  0.21505       
218710  0.029961  0.21505       
238384  0.029961  0.21505       
350532  0.029961  0.21505       
trans-4-hydroxyproline  0.035828  0.24109       
citric acid  0.035828  0.24109       
199777  0.035828  0.24109       
xanthine  0.04257  0.24123       
threonic acid   0.04257   0.24123       
Unknown metabolites are listed by Binbase identification numbers        
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Supplementary table 2. Metabolites with AUC greater than 0.75  
HC vs. IBD-PRE  IBD-PRE vs. IBD-POST 
Metabolite  AUC   T-tests  
Fold 
Change   Metabolite  AUC   T-tests  
Fold 
Change  
tyrosine/362092 1.000 2.86E-07 1.574  tryptophan/224551 0.9931 2.48E-07 -0.80634 
362092 1.000 0.0002 -0.879  224551/506977 0.9861 1.11E-08 1.2992 
213961/512073 0.992 1.02E-06 1.973  beta-alanine/506977 0.9722 1.40E-07 1.2398 
3-hydroxybutanoic acid/213961 0.983 7.61E-07 -2.908  224551/219507 0.9722 2.30E-07 0.5452 
gluconic acid lactone 0.967 0.0034 -2.288  211946/506977 0.9722 1.08E-07 0.98879 
hexuronic acid 0.950 0.0013 -0.899  281216/506977 0.9722 1.93E-07 1.5229 
3-hydroxybutanoic acid 0.950 0.0008 -1.464  213300/506977 0.9722 1.84E-07 0.70382 
hexuronic acid/225396 0.933 1.38E-06 -2.970  438106/506977 0.9722 2.41E-07 1.3996 
225396 0.925 0.0002 2.071  tocopherol alpha/224551 0.9653 1.71E-07 -0.16097 
ribose 0.904 0.0006 -1.102  268365/506977 0.9653 4.60E-07 1.1085 
672987 0.900 0.0007 2.385  309730/438081 0.9653 2.26E-06 0.91595 
281216/506977 0.900 0.0016 -3.882  438081/506977 0.9653 2.94E-07 0.85977 
213961 0.883 0.0007 1.444  506977/281910 0.9653 3.52E-07 -1.1376 
224551/213961 0.875 0.0008 -2.416  506977 0.9583 1.87E-06 -0.9601 
tryptophan/224551 0.867 0.0023 1.716  224551/213961 0.9583 6.64E-07 1.1176 
225262 0.867 0.0022 0.853  275375/506977 0.9583 1.88E-07 1.0351 
aminomalonic acid 0.867 0.0064 0.653  213961/512073 0.9514 2.39E-05 -1.0766 
438106 0.867 0.0032 -0.716  309730 0.9097 0.0002 0.81562 
281216 0.867 0.0006 -0.792  
3-hydroxybutanoic 
acid/213961 0.9097 0.0005 2.1115 
438106/506977 0.867 0.0019 -3.806  208381 0.8958 0.0003 -1.1375 
tryptophan 0.858 0.0159 0.744  224551 0.8889 0.0001 0.33915 
gluconic acid 0.858 0.0290 -2.768  213961 0.8889 0.0014 -0.77844 
224551/506977 0.858 0.0012 -4.062  455836 0.875 0.0081 -0.22728 
tyrosine 0.850 0.0029 0.695  362056 0.875 0.0009 0.11834 
2-hydroxybutanoic acid 0.850 0.0022 -0.955  gluconic acid lactone 0.8403 0.0085 1.158 
208655 0.842 0.0061 -0.622  xylitol 0.8125 0.0181 0.54909 
200547 0.842 0.0164 -0.869  362075 0.8056 0.0078 -0.11143 
5-methoxytryptamine 0.833 0.0050 -1.117  474607 0.7917 0.0201 -0.012867 
367978 0.833 0.0075 -2.949  219507 0.7847 0.0153 -0.20606 
506977/281910 0.825 0.0062 2.798  241310 0.7778 0.0783 0.042176 
267808 0.825 0.0085 0.663  321748 0.7708 0.0554 -0.81115 
212274 0.825 0.0055 -0.764  histidine 0.7639 0.8811 -0.69454 
314770 0.825 0.0078 -0.773  tocopherol alpha 0.7569 0.0358 0.17818 
307909 0.825 0.0139 -1.070  naphtalene 0.7569 0.0039 -0.52466 
224551/219507 0.825 0.0191 -1.451  438081 0.7569 0.0162 -0.10033 
438081/506977 0.825 0.0037 -3.144  Unknown metabolites are listed by Binbase identification numbers  
210286 0.817 0.0140 -0.685      
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Supplementary table 2. Continued       
HC vs. IBD-PRE 
Metabolite  AUC   T-tests  
Fold 
Change  
cellobiotol 0.817 0.0143 -0.960      
211946/506977 0.817 0.0047 -3.207      
362075 0.808 0.0248 1.038      
xylitol 0.808 0.0133 -0.990      
213300/506977 0.808 0.0058 -2.981      
fucose+ rhamnose 0.800 0.0177 -0.441      
cysteine 0.800 0.0102 -1.058      
208381 0.792 0.0036 2.299      
235449 0.792 0.0375 -0.766      
2-deoxyerythritol NIST 0.792 0.0094 -0.798      
268365/506977 0.792 0.0066 -3.037      
275375/506977 0.792 0.0057 -3.097      
beta-alanine/506977 0.792 0.0048 -3.375      
350396 0.788 0.0099 -1.422      
350532 0.783 0.0340 1.853      
p-hydroquinone 0.783 0.0386 1.716      
508772 0.783 0.4237 -0.158      
uracil 0.783 0.0263 -0.485      
241029 0.783 0.0295 -0.690      
nicotinic acid 0.779 0.0141 -0.776      
4-hydroxyproline 0.775 0.0268 0.829      
208557 0.775 0.0147 0.746      
homovanillic + 4-
hydroxymandelic acid 0.775 0.0094 0.545      
226845 0.775 0.1462 0.341      
224849 0.775 0.0178 0.335      
xylose 0.775 0.0349 -0.753      
460930 0.771 0.0125 -0.638      
trans-4-hydroxyproline 0.767 0.0183 1.223      
211972 0.767 0.0182 0.456      
citric acid 0.767 0.0936 -0.554      
phenylethylamine 0.767 0.0356 -0.972      
226912 0.758 0.0185 1.849      
218710 0.758 0.0467 -0.788      
Unknown metabolites are listed by 
Binbase identification numbers          
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Supplementary table 3. List of 75 metabolites inclueded in heatmap figure 7B 
# on x-axis Metabolite 
1 aminomalonic acid 
2 glutamine 
3 histidine 
4 225262 
5 226912 
6 homovanillic acid 
7 tryptophan 
8 362075 
9 321748 
10 672987 
11 225396 
12 proline 
13 trans-4-hydroxyproline 
14 4-hydroxyproline 
15 267808 
16 211972 
17 208557 
18 tyrosine 
19 3-hydroxybutanoic acid 
20 2-hydroxybutanoic acid 
21 mannitol 
22 ribose 
23 2-deoxyerythritol NIST 
24 479886 
25 isothreonic acid 
26 citric acid 
27 330967 
28 219507 
29 inositol allo- 
30 362056 
31 208381 
32 455836 
33 nicotinic acid 
34 444613 
35 212274 
36 213961 
37 506977 
38 naphtalene 
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39 309730 
40 229203 
41 allantoin 
42 glucose 
43 362092 
44 xylitol 
45 367978 
46 267647 
47 cellobiotol 
48 5-methoxytryptamine 
49 fructose 
50 199802 
51 gluconic acid lactone 
52 gluconic acid 
53 438106 
54 281216 
55 224551 
56 tocopherol alpha 
57 behenic acid 
58 5-hydroxynorvaline NIST 
59 cysteine 
60 homocystine 
61 350396 
62 241310 
63 270003 
64 200547 
65 474607 
66 299091 
67 353747 
68 314770 
69 210286 
70 227604 
71 208655 
72 307909 
73 hexuronic acid 
74 xylose 
75 fucose+ rhamnose 
Unknown metabolites are listed by Binbase identification numbers 
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Supplementary table 4. Signalment of dogs enrolled in this study  
 
Phenotype 
 
Age  Body weight 
Breed Sex  Neuter status 
CIBDAI 
Immunosuppressive 
Drug  Antibiotics use 
Diet  
(yr)  (kg) PRE POST (brand_product name) Crude Protein (%) 
Crude 
Fat (%) 
Crude Fiber 
(%) 
IBD_1 11 10 
Scottish 
terrier M Neutered 3 0 prednisone no Hill's_d/d (duck and potato) 18.0 16.4 1.7 
IBD_2 7 23 Collie F Neutered 6 0 budesonide no Hill's_d/d 18.4 15.5 1.8 
IBD_3 10 6 MIX F Intact 1 0 prednisone no Hill's_d/d 18.4 15.5 1.8 
IBD_4 14 5 WHWT F Neutered 3 0 prednisone  no Royal Canin_hypoallergenic 19.0 10.0 3.7 
IBD_5 11 9 WHWT M Neutered 13 0 prednisone  metronidazole Hill's_d/d (duck and potato) 18.0 16.4 1.7 
IBD_6 9 5 MD M Neutered 5 1 prednisone metronidazole Hill's_d/d 18.4 15.5 1.8 
IBD_7 4 4 YT F Neutered 8 1 
prednisone + 
cyclosporin metronidazole Hill's_d/d 18.4 15.5 1.8 
IBD_8 4 4 Shih Tzu F Neutered 9 5 prednisone metronidazole Hill's_d/d (duck and potato) 18.0 16.4 1.7 
IBD_9 9 3 YT M Neutered 9 2 
prednisone + 
cyclosporin no Hill's_d/d 18.4 15.5 1.8 
IBD_10 3 9 Beagle M Neutered 6 2 prednisolone no Iams_KO diet 19 12 4 
IBD_11 3 5 Havanese F Neutered 9 1 prednisone no Royal canin_duck/potato 19 10 3.7 
IBD_12 6 8 Beagle F Neutered 5 1 prednisone  metronidazole Hill's_d/d (duck and potato) 18.0 16.4 1.7 
HC_1 2 7 MIX F Neutered n/a n/a n/a no Purina_maintenance  26 16 3 
HC_2 3 28 MIX F Neutered n/a n/a n/a no Purina_maintenance 26 16 3 
HC_3 2 26 MIX F Neutered n/a n/a n/a no 
Eukanuba_large breed lamb 
and rice 22.5 12 4 
HC_4 8 13 MIX M Neutered n/a n/a n/a no Hills_science diet 20.0 6.0 18.5 
HC_5 4 42 MIX F Neutered n/a n/a n/a no Hill’s_d/d duck and potato  18.0 16.4 1.7 
HC_6 5 27 MIX M Neutered n/a n/a n/a no Purina_savory blend kibble 26 16 3 
HC_7 3 34 MIX M Neutered n/a n/a n/a no Hill’s_science diet 20.0 6.0 18.5 
HC_8 4 28 MIX F Neutered n/a n/a n/a no 
Purina_pro-plan sensitive skin 
and stomach 26 16 4 
HC_9 1 24 MIX M Neutered n/a n/a n/a no 
Purina_pro-plan sensitive skin 
and stomach 26 16 4 
HC_10 10 15 MIX M Neutered n/a n/a n/a no 
Purina_pro-plan sensitive skin 
and stomach 26 16 4 
IBD, dogs with IBD; HC, healthy control dogs; MIX, mixed breed; WHWT, West Highland White Terrier; MD, Miniature Dachshund; M, male; F, female; YT, Yorkshire Terrier; n/a, not applicable 
 
